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2. Abbreviations 
 
AD:   atopic dermatitis 
AE:   atopic eczema 
AICD:   activation-induced cell death 
APC:   antigen-presenting cell 
CLA:   cutaneous lymphocyte-associated antigen 
CTL:   cytotoxic T lymphocyte 
CTLA-4:   cytotoxic T lymphocyte antigen-4 
DC:   dendritic cell 
EAD:   extrinsic (allergic) type atopic dermatitis 
ECM:   extracellular matrix 
EDC:   epidermal dendritic cell 
FasL:   Fas ligand 
GITR glucocorticoid-induced tumour necrosis factor receptor 
GM-CSF: granulocyte macrophage-colony stimulating factor 
GVHD: graft-versus-host disease 
HDM:    house dust mite 
IAD:   intrinsic (non-allergic) type atopic dermatitis 
ICOS:   inducible costimulator 
IFN-!:   interferon-! 
Ig:   immunoglobulin 
IL:    interleukin 
IP-10   interferon-!-inducible protein-10 
IPEX: immune dysregulation, polyendocrinopathy, enteropathy X-
linked syndrome 
iTac   interferon-!-inducible-"-chemoattractant 
KC:    keratinocyte 
LC:   Langerhans’ cell 
mAb:   monoclonal antibody 
MBP:   myelin basic protein 
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Mig   monokine induced by !-interferon 
NK:   natural killer 
PBMC:  peripheral blood mononuclear cells 
PD-1:   programmed death-1 
PI3K:   phosphatidylinositol 3-kinase 
PIT:   peptide immunotherapy 
SIT:   specific immunotherapy 
TCR:   T cell receptor 
TGF-#:   transforming growth factor-# 
Th:   T helper  
TLR:   Toll-like receptor 
TNF-":   tumour necrosis factor-" 
Tr1:    type 1 regulatory T cell 
Treg:    T regulatory  
VCAM-1:  vascular cell adhesion molecule-1 
XLAAD:  X-linked autoimmunity–allergic dysregulation syndrome 
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3. Summary 
 
Allergic disease is controlled, mediated and in some cases executed by T cells. 
Upon the recognition of allergen, T helper 2 (Th2) cells induce the secretion of 
immunoglobulin (Ig)E by B cells, leading to mast cell activation and the release of 
inflammatory mediators, such as histamine and leukotrienes. This forms the 
basis of the common allergic type 1 hypersensitivity response. Th1 cells play an 
important role in the chronicity of allergic inflammation and are responsible for 
the major tissue injury event in atopic dermatitis; the induction of apoptosis in 
epidermal keratinocytes. T regulatory cells play an important role in the control of 
inflammation and, as shown in this thesis, are key regulators of the healthy 
immune response to allergens. 
  
Atopic dermatitis is a chronic inflammatory skin disease characterised by Th1 
cell-induced keratinocyte apoptosis. This key tissue injury event is mediated 
through interferon-! (IFN-!) and Fas, expressed by Th0/Th1 cells in the dermal 
and epidermal layers of the skin. We showed that keratinocytes undergoing 
apoptosis actively aggravate the inflammation. Keratinocyte stimulation with IFN-
! induces the upregulation of chemokines such as interferon-!-inducible protein-
10 (IP-10), monokine induced by !-interferon (Mig) and interferon-!-inducible " 
chemoattractant (iTac). These chemokines attract T cells bearing the specific 
receptor CXCR3. This facilitates the further infiltration of T cells into the skin and 
towards the epidermis, leading to the formation of eczematous lesions. 
 
The balance between Th2 and Th1 cells has long been considered decisive for 
an allergic or healthy immune response to allergens. Although Th1 cells 
suppress the proliferation of Th2 cells and can therefore prevent a type 1 
hypersensitivity response, the induction of a Th1 response could lead to a type IV 
hypersensitivity with equally undesired effects. We have shown that it is rather 
the balance between allergen-specific IL-10-secreting T regulatory type 1  (Tr1) 
cells and Th2 cells that decides the outcome of an allergen encounter. Healthy 
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individuals have a higher prevalence of allergen-specific Tr1 cells, while allergic 
individuals show a majority of allergen-specific Th2 cells. The Tr1 cells are highly 
effective suppressors of T cell activation and utilise a combination of the secreted 
suppressive cytokines IL-10 and TGF-#, but also rely on the cell surface 
receptors CTLA-4 and PD-1.  Since we have further shown that these Tr1 cells 
can be expanded in vitro with a range of cytokines (IL-2, IL-4, IL-7 and IL-15), the 
induction of allergen-specific Tr1 cells forms a potential treatment modality in 
allergen-specific immunotherapy (SIT).  
 
Although we and others have shown that both Tr1 cells and CD4+CD25+FoxP3+ 
Treg cells are capable of suppressing T cell activation in vitro, as well as that the 
number of Treg cells in the blood positively correlates with reduced allergic and 
autoimmune disease, little is known about the presence and role of Treg cells in 
the tissues. We examined lesional skin biopsies of patients suffering from atopic 
dermatitis or a number of other conditions and found that although there are 
numerous IL-10- and TGF-#-secreting Tr1 cells in the dermis and epidermis, 
there are no CD4+CD25+FoxP3+ Treg cells.  
Subsequently, we have performed co-culture experiments of both types of 
Treg cells, in combination with keratinocytes and activated Th1 cells, in order to 
determine whether these cells, which are highly capable of suppressing T cell 
activation, are capable of suppressing the major tissue injury event in atopic 
dermatitis, Th1 cell-induced keratinocyte apoptosis. Experiments of keratinocytes 
combined with T cells or only cytokines showed that both types of Treg cells are 
incapable of suppressing the effector functions of pre-activated T cells. 
 
In conclusion, we have demonstrated that Treg cells play an important role in the 
maintenance of T cell unresponsiveness to allergens. The induction of allergen-
specific Treg cells by allergen-SIT could lead to an immunological state where an 
allergic response upon allergen encounter is no longer generated. However, 
when pre-activated T cell are actively drawn to the tissue under the influence of a 
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chemokine network, Treg cells cannot suppress the destructive effects of 
apoptosis-inducing effector T cells.       
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4. Zusammenfassung 
 
Allergische Erkrankungen werden von T Zellen kontrolliert, vermittelt und in 
einigen Fällen auch verursacht.  Nach dem Erkennen eines Allergens induzieren 
T Helfer 2 Zellen (Th2) die Freisetzung von Immunglobulin (Ig) E durch B-Zellen. 
Das wiederum führt zur Aktivierung von Mastzellen und der Freisetzung 
entzündlicher Mediatoren, wie Histamin und Leukotrienen. Dieses bildet die 
Grundlage der allergischen Hypersensitivitäts-Antwort 1. Th1 Zellen spielen eine 
wichtige Rolle in der chronischen allergischen Entzündung. Sie sind deshalb 
auch hauptsächlich für die Beschädigung des Gewebes in der atopischen 
Dermatitis verantwortlich, die vor allem durch die Induktion von Apoptose in den 
epidermalen Keratinozyten zu Stande kommt. Regulatorische T Zellen nehmen 
eine wichtige Position bei der Kontrolle der Entzündung ein und spielen eine 
Schlüsselrolle als Regulatoren einer gesunden Immunantwort auf Allergene.  
Atopische Dermatitis ist eine chronisch-entzündliche Hauterkrankung, die durch 
Th1 induzierte Keratinozyten-Apoptosis charakterisiert ist. Die Beschädigung von 
Gewebe wird hauptsächlich durch IFN-! und Fas vermittelt, welche von Th0/1 
Zellen in der Dermis und Epidermis gebildet werden. Wir zeigten, dass 
Keratinozyten, die in Apoptose übergehen aktiv die Entzündung verschlimmern. 
Die Stimulierung von Keratinozyten durch IFN-! induziert die Bildung von 
Chemokinen, wie IP-10 (interferon-!-inducible protein), Mig (monokine induced 
by interferon-!) und iTac (interferon-!-inducible-"-chemoattractant). Diese 
Chemokine locken T Zellen mit dem spezifischen Rezeptor CXCR3 an. Das 
erleichtert das weitere Eindringen von T Zellen in die Haut und bis in die 
Epidermis und führt zur Entstehung ekzematöser Läsionen. 
Das Gleichgewicht zwischen Th2 und Th1 Zellen wurde lange Zeit für 
entscheidend gehalten, ob es zu einer allergischen oder einer gesunden 
Immunantwort auf ein Allergen kommt. Obgleich Th1 Zellen die Proliferation von 
Th2 Zellen unterdrücken, und damit die Typ-1-Hypersensitivitäts-Antwort 
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verhindern, könnte die Induktion einer Th1 Antwort zu einer Typ IV 
Hypersensitivität mit genauso unerwünschten Folgen führen. Wir haben gezeigt, 
dass stattdessen das Gleichgewicht zwischen Allergen-spezifischen IL-10-
absondernden regulatorischen T Zellen vom Typ 1 und Th2 Zellen entscheidend 
für das Ergebnis nach dem Zusammentreffen mit einem Allergen ist. Gesunde 
Personen haben eine höhere Prävalenz von allergen-spezifischen Tr1 Zellen, 
während allergische Personen vor allem allergen-spezifische Th2 Zellen 
aufweisen. Tr1 Zellen sind hoch-wirksame Suppressoren der T Zellaktivierung. 
Sie verwenden eine Kombination von freigesetzten Suppressor-Zytokinen IL-10 
und TGF-#, aber auch die Zelloberflächenrezeptoren CTLA-4 und PD-1 zur 
Unterdrückung. Wie wir schon vorher gezeigt haben, können diese Tr1-Zellen in 
vitro mit Hilfe verschiedener Zytokine (IL-2, IL-4, IL-7 und IL-15) expandiert 
werden. Die Induktion von allergen-spezifischen Tr1 Zellen stellt somit eine 
Behandlungsmöglichkeit in der allergen-spezifischen Immuntherapie (SIT) dar.  
Obwohl wir und auch andere gezeigt haben, dass Tr1 und CD4+CD25+FoxP3+ 
Treg Zellen in der Lage sind T Zellenaktivierung in vitro zu unterdrücken und 
weiterhin die Anzahl der Treg Zellen im Blut positiv mit reduzierter allergischer 
und Autoimmun-Erkrankung korreliert, so ist doch wenig über das Auftreten und 
die Rolle von Treg Zellen im Gewebe bekannt. Wir untersuchten betroffene 
Hautbiopsien von Patienten, die an atopischer Dermatitis oder anderen 
Erkrankungen litten, und fanden, dass obwohl zahlreiche IL-10 und TGF-# 
sekretierende Tr1 Zellen in der Dermis und Epidermis auftraten, keine 
CD4+CD25+FoxP3+ vorhanden waren. Anschliessend führten wir Co-Kultur-
Experimente mit beiden Treg Zelltypen in Kombination mit Keratinozyten und 
aktivierten Th1 Zellen durch. Ziel war es herauszufinden welche dieser Zellen, 
die normalerweise in der Lage sind die T Zellenaktivierung zu unterdrücken auch 
die Gewebsverletzungen in der atopischen Dermatitis unterdrücken können, die 
durch die Th1 Zellen–induzierte Keratinozyten-Apoptose hervorgerufen werden. 
Experimente mit Keratinozyten kombiniert mit T Zellen oder nur Zytokinen 
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zeigten, dass beide Typen regulatorischer T Zellen nicht in der Lage sind 
Effektorfunktionen von zuvor aktivierten T Zellen zu unterdrücken.  
Zusammenfassend haben wir demonstriert, dass regulatorische T Zellen eine 
bedeutende Rolle bei der Erhaltung der Unempfänglichkeit von T Zellen für 
Allergene spielen. Die Induktion von Allergen-spezifischen Treg durch SIT könnte 
zu einem immunologischen Status führen bei dem das Zusammentreffen mit 
einem Allergen nicht mehr zu einer allergischen Reaktion führt. Wenn aber zuvor 
aktivierte T Zellen unter dem Einfluss eines Chemokin-Netzwerkes aktiv in das 
Gewebe einwandern dann können regulatorische T Zellen die zerstörerischen 
Effekte der Apoptose-induzierenden Effektor T Zellen nicht mehr unterdrücken. 
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5. Introduction 
 
5.1 Allergy 
 
Allergy is often seen as an illness that results from our changing lifestyle and 
environment. Although there is undoubtedly an increase in prevalence during the 
last five decades, allergic disease has probably existed as long as humanity. 
Possibly the earliest documented case of allergic disease in history dates back 
from some time between 3640 and 3300 BC, when the Egyptian pharaoh 
Menses died after being stung by a wasp. Another historic case is that of 
Britannicus (AD 41-55), son of the Roman emperor Claudius, who was allergic to 
horses and developed a rash and eye swelling to the extent that he could not see 
where he was going during official parades, reason enough to have to leave the 
throne to his stepbrother Nero. Both cases demonstrate how allergic disease can 
have a dramatic effect on people’s lives. 
In 1906, the Viennese paediatrician Clemens von Pirquet first used the 
term allergy to describe “an altered capacity of the body to react to a foreign 
substance”. This broad term was later redefined as “disease following an immune 
response to an otherwise innocuous non-self antigen”. Although often 
associated, the term atopy should not be confused with allergy. Atopy describes 
the increased susceptibility of an individual to developing an IgE-mediated 
immune response to antigens, which may lead to a type I immediate 
hypersensitivity response (table 1). However, not all allergic reactions are type I 
hypersensitivity responses. Both asthma and atopic dermatitis have non-atopic 
components and are a combination of immediate (type 1) and delayed (type IV) 
hypersensitivity. Allergic contact dermatitis is not IgE-mediated and is 
characterised by a type IV response, while allergic alveolitis and allergic 
vasculitis are both type III reactions 1.  
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Table 1. Hypersensitivity responses 
 Type I Type II Type III Type IV 
Immune reactant IgE IgG IgG Th1 cells Th2 cells CTL 
Antigen Soluble antigen Cell- or matrix-
associated 
antigen 
Soluble antigen Soluble 
antigen 
Soluble 
antigen 
Cell-
associated 
antigen 
Effector 
mechanism 
Mast cell and 
basophil 
degranulation 
FcR
+
 cells 
(phagocytes, 
NK cells) 
FcR
+
 cells 
compliment 
Macrophage 
activation 
Eosinophil 
activation 
cytotoxicity 
Examples of 
hypersensitivity 
reaction 
Allergic rhinitis, 
asthma, 
systemic 
anaphylaxis 
Some drug 
allergies (e.g. 
penicillin) 
Serum 
sickness, 
Arthus reaction 
Contact 
dermatitis, 
tuberculin 
reaction 
Chronic 
asthma, 
chronic 
allergic rhinitis 
Contact 
dermatitis 
Adapted from Immunobiology: the immune system in health and disease 5
th
 edition, eds. CA 
Janeway Jr, P Travers, M Walport, MJ Slomchik. Garland Publishing, New York, NY, USA. 
 
 
 
5.2 Cells and cytokines in allergic inflammation 
 
In the 1980s, it was first discovered that separate populations of helper T cells 
could be distinguished on the basis of their cytokine secretion pattern. These 
subsets are derived from the same precursor, naïve CD4+ T cells, and 
differentiate upon the first encounter of their specific antigen. The cytokines in the 
microenvironment, produced by antigen-presenting cells (APC) and resident 
tissue cells, determine the phenotype of the activated CD4+ T cell. Traditionally, a 
distinction was made between only two types of CD4+ T cells, but more recently 
a third population, the T regulatory (Treg) cells, has been described and defined.  
The generation of the right subset of T cells upon antigen encounter is crucial for 
an appropriate immune response. Domination of the wrong subset can lead to 
inadequate clearance of a pathogen, autoimmune disease or hypersensitivity.   
 Although T cells certainly make up the largest number of cells involved in 
the response against allergens, more cell types play an essential role in the 
correct outcome of an immune reaction. Both B cells and dendritic cells are 
increasingly seen as important determinants in the establishment of allergic 
inflammation or a healthy immune response. The role of these cells and their 
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mediators in the immune response against allergens will now be briefly 
discussed. 
 
 
5.2.1 T helper 2 cells 
 
T helper 2 (Th2) cells are a subset of T cells that secrete a particular set of 
cytokines, including IL-4, IL-5 and IL-13. Their development depends on the 
cytokine IL-4, which activates the transcription factors GATA-3 2 and STAT6 3. 
The source that provides the initial IL-4 is still under debate, since Th2 cells 
themselves are the major producers of this cytokine. The principle function of 
Th2 is to induce IgE production by B cells/ plasma cells upon recognition of their 
specific antigen. The ligation of IgE to the high-affinity IgE receptor (Fc$RI) on the 
surface of basophils and mast cells induces the release of inflammatory 
mediators, such as cytokines, leukotrienes and histamine. IgE and Th2 cytokines 
are thought to aid in the eosinophil-mediated immune response against helminth 
infections, but IgE also triggers the immediate hypersensitivity response to 
allergens.  
 
5.2.1.1. Interleukin-4 
Interleukin-4 (IL-4) is an 18 kD cytokine produced mainly by Th2 cells and also 
by activated mast cells and basophils.  IL-4 induces Th2 differentiation from 
naive CD4+ precursors, stimulates IgE production by B cells and mast 
cell/eosinophil mediated reactions and suppresses IFN-!-dependent macrophage 
functions.  In addition, IL-4 induces expression of the low-affinity IgE receptor 
(CD23) on B cells and vascular cell adhesion molecule-1 (VCAM-1) on 
endothelial cells. A reduced IgE synthesis has been shown in IL-4-deficient mice.  
IL-4 in combination with GM-CSF can be used to establish DC lines from 
adherent mononuclear cells, which express high levels of MHC molecules, 
CD1a, CD40, B7 and ICAM-1 4. The IL-4 receptor, CD124, shares a common #, 
and occasionally, ! chain with several other cytokine receptors.  
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5.2.1.2. Interleukin-5 
Interleukin-5 (IL-5) is a 45-50 kD cytokine produced by Th2 cells and activated 
mast cells. IL-5 stimulates the growth and differentiation of eosinophils and 
activates mature eosinophils. IL-5 works in concert with IL-4; IL-4 increases IgE 
production, IgE opsonises helminths and binds eosinophils and IL-5 activates 
eosinophils to kill the parasites. IL-5-deficient mice have defective eosinophil 
responses and are therefore susceptible to helminth infections. IL-5 also 
stimulates B cell proliferation and IgA production. Anti-IL-5 monoclonal antibodies 
have been found to lower blood and sputum eosinophil numbers in humans and 
may therefore have a therapeutic potential for asthma and allergy 5. 
 
5.2.1.3. Interleukin-13 
Interleukin-13 (IL-13) is a 15 kD cytokine closely related to IL-4 and produced by 
Th2 cells, as well as mast cells and natural killer (NK) cells.  IL-13 induces 
isotype switching on B cells to IgE. The main actions of IL-13 are to inhibit 
macrophage activation and to antagonise IFN-!.  IL-13 further stimulates mucus 
production by lung epithelial cells and may therefore also play a role in asthma.  
IL-13-deficient mice show a decreased IgE production and lower susceptibility to 
allergic reactions and asthma 6. 
 
 
5.2.2 T helper 1 cells 
 
The T helper 1 (Th1) subset of T cells is characterised by the secretion of IFN-!. 
They are mostly generated upon infection with intracellular bacteria, 
mycobacteria and some parasites. These microbes are recognised by Toll-like 
receptors (TLRs) on the surface of macrophages and dendritic cells, which 
secrete IL-12 in response. Ligation of the IL-12 receptor on CD4+ T cells 
activates the transcription factors T-bet 7 and STAT4 8, and these promote the 
differentiation into Th1 cells.  
 19 
The major Th1 cytokine, IFN-!, stimulates macrophages to digest engulfed 
microbes, but also promotes the formation of non-inflammatory IgG4 class 
antibody against antigens. A Th1-dominated response against allergens is 
therefore sometimes seen as protective for allergic disease. Th1 cells however 
play an important role in delayed type hypersensitivity (type IV) reactions. For 
example, the IFN-! they produce, in combination with the expression of FasL, is 
responsible for the major tissue injury event in AD, the apoptosis of keratinocytes 
and consequent spongiosis formation 9. 
 
5.2.2.1. Interferon-!  
Interferon-! (IFN-!) is a classic Th1 cytokine and the principal activator of 
macrophages and has critical functions in innate and adaptive cell-mediated 
immunity.  IFN-! is also a crucial mediator of NK cell responses to intracellular 
pathogens. IFN-! gene expression in T cells can be induced by IL-1, IL-2, IL-12, 
IL-18, TNF-", antigens and mitogens, while IL-4, IL-10, corticosteroids, 
cyclosporine A and vitamin D inhibit IFN-! expression. IFN-! has an anti-viral 
activity, which is mediated by the induction of oxygen metabolites and nitric oxide 
in macrophages and neutrophils. Macrophages are activated by IFN-! to kill 
tumour cells and intracellular parasites. IFN-! influences T cell proliferation, 
differentiation and effector functions, by inhibiting Th2 cytokine expression and 
IgE synthesis. The receptor for IFN-! is expressed on most cell types, thus 
providing a broad spectrum of effects. 
 
 
5.2.3 T regulatory cells 
 
T cells that are able to suppress the immune response were first described in the 
early 1970s 10. This area of research was abandoned in the 1980s, when the 
mechanisms underlying immune suppression failed to be clarified, because of 
the insufficient analysis techniques available to researchers 11.  Exploration into 
the concept of T cell-mediated immune suppression strengthened once more in 
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the 1990s after new technological developments.  Although the idea of Treg cells 
regulating immune responses via cell-cell interactions and/or the production of 
cytokines is currently well established, many aspects behind these mechanisms 
remain to be revealed. Various subpopulations of Treg cells, with different 
modes of operation, have been described (table 2). The three most common 
subtypes are discussed below.  
 
5.2.3.1. Type1 regulatory cells (Tr1) 
Tr1 cells, also known as adaptive or inducible Tregs, are defined by their ability 
to produce high levels of IL-10 with or without the production of TGF-# 12, 13 and 
are therefore also known as IL-10-secreting cells. They develop in the periphery 
under the influence of presumably immature dendritic cells and/or the presence 
of IL-10 and TGF-# 14. A Tr1 cell subset can be generated in vitro by stimulating 
naive CD4+ T cells in the presence of IL-10, IFN-" or a combination of IL-4 and 
IL-10 12, 13. A combination of dexamethasone and vitamin D3 can induce human 
and mouse naive CD4+ T cells to differentiate in vitro into Tr1 cells 15, which, in 
contrast to previously described in vitro derived CD4+ T cells, only produced IL-
10, but no IL-5 or IFN-!. Human IL-10-producing Tr1 cells are generated in vivo 
during the early course of allergen-SIT, implying that high and increasing doses 
of allergens induce Tr1 cells 16-18. The near future holds the use of Tr1 cells as a 
novel target for developing new therapeutic agents, and as a cellular therapy for 
the induction of peripheral tolerance in allergy and autoimmunity 19-21.  
 
5.2.3.2. CD4+CD25+ Treg cells 
This subset of Treg cells, also known as the natural Tregs, accounts for 5–15% 
of peripheral blood CD4+ T cells. They were the first type of Treg cell to be 
shown to inhibit the activation and proliferation of effector T cells 22-25. The 
phenotype of these cells is not only characterised by the expression of the 
surface proteins CD4 and CD25 (IL-2R"-chain), but also by the expression of 
the transcription factor FoxP3 26. They further express the surface markers 
cytotoxic T lymphocyte antigen-4 (CTLA-4) 27 and glucocorticoid-induced tumour 
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necrosis factor receptor (GITR) 28, which play a role in their suppressor activity. 
CD4+CD25+ Treg cells mostly develop in the thymus and in mouse models,  
depletion of these cells leads to hyperproliferation of normal lymphocytes and 
destruction of various tissues 29. In humans, a mutation in FoxP3 leads to the 
rare immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) 
syndrome, which is associated with the development of atopic dermatitis and 
hyper IgE responses, as well as type 1 diabetes and other autoimmune diseases 
30. Although CD4+CD25+ Treg cells have been shown to inhibit the activation and 
proliferation of effector T cells in vitro, they may partially rely on the induction of 
Tr1 cells for their suppressive effect in vivo 31. 
 
5.2.3.3. Th3 cells 
These Treg cells are characterised by the production of high levels of TGF-# 
upon activation with antigen or anti-CD3 antibody 32. Th3 cells were found to 
suppress encephalitis induction with myelin basic protein (MBP).  TGF-# and IL-
10 seem to play a crucial role, as neutralising antibodies against these cytokines 
abrogate the protective effects of these cells. In vitro, Th3 cells have been shown 
to exert bystander immune suppression.  
 
 
Table 2. Types of regulatory T cells 
Treg cell type Suppressor mechanism 
Tr1  IL-10, TGF-# 
CD4+CD25+ IL-10, TGF-#, CTLA-4, PD-1, GITR 
Th3 TGF-# 
CD8+CD25+CD28- Same as CD4+CD25+ 
Qa-1-dependent CD8+ Qa-1-specific TCR 
CD4-CD8- Induction of apoptosis 
TCR !%  IL-10, TGF-# 
Adapted from Taylor A et al, Microbes Infect. 2005; 7:1049-55 
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5.2.4 B cells 
 
As the only antibody-producing cell type, B cells play an important role in allergic 
inflammation. In type I hypersensitivity responses, they produce the IgE 
responsible for mast cell release of histamine and other inflammatory mediators, 
under the influence of Th2 cell cytokines. Apart from this pro-inflammatory role, a 
regulatory role for IL-10-secreting B cells has been recently proposed 33. These B 
cells were shown to prevent the development of arthritis. Their suppressive effect 
is highly dependent on IL-10, since B cells isolated from IL-10-deficient mice fail 
to protect from arthritis. Helminth infection of mice has been shown to lead to an 
increased number of IL-10-producing B cells 34. Upon adoptive transfer, these B 
cells protected mice from developing allergic hypersensitivity and anaphylaxis. In 
another mouse model, a deficiency in regulatory B cells was shown to correlate 
with an increased susceptibility to allergic airway inflammation 35.  
 
 
5.2.5 Dendritic cells 
 
Dendritic cells (DC) are the sentinels of the immune system, usually located at 
the interfaces of the body such as the skin and mucosa, and play an important 
role in the initiation and regulation of the immune response. They are considered 
the connecting link between allergen exposure and disease in the allergic form of 
atopic dermatitis (AD, see also section 5.3.1) 36. Patients with allergic AD show a 
much higher expression of the high-affinity IgE receptor Fc$RI on the two 
subtypes of DC in the skin, Langerhans’ cells (LC) and epidermal dendritic cells 
(EDC), than healthy individuals or non-allergic AD patients 37. Skin DC actively 
contribute in the shift from a Th2 to Th0/Th1 response, typical for AD, by the 
secretion of IL-12 and IL-18 upon ligation of Fc$RI 38. Similar to AD, dendritic 
cells have also been shown to play a critical role in the initiation of an allergic or a 
healthy response against aeroallergens in the lung 39.  
There are some indications that DC can induce peripheral T cell tolerance 
and that a regulatory DC subset may exist. Pulmonary dendritic cells from mice 
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exposed to respiratory antigen transiently produce IL-10 40. These phenotypically 
mature pulmonary B7hi DC stimulate the development of CD4+ Tr1-like cells that 
also produce high amounts of IL-10. Adoptive transfer of pulmonary DC from IL-
10+/+, but not IL-10-/-, mice exposed to respiratory antigen induced antigen-
specific unresponsiveness in recipient mice. Accordingly, IL-10 inhibits the 
development of fully mature DC, which induces a state of alloantigen-specific 
anergy in CD4+ T cells 41. These studies show that IL-10 production by DC is 
critical for the induction of tolerance, and that phenotypically mature DCreg may 
exist under certain circumstances. 
 
 
5.3 Allergic disease 
 
The exact reason why some individuals develop allergic immune responses to 
common environmental antigens, while others tolerate these, is not known. 
However, several options have been suggested in the recent past. Studies have 
uncovered various susceptibility genes that increase the risk of developing 
asthma or atopic disease within certain families. For example, single nucleotide 
polymorphisms in the IL18 gene have been suggested to relate to the 
development of atopic eczema, in particular to the intrinsic subtype 42. The gly16 
allele of the #2-adrenergic receptor gene predisposes to nocturnal asthma, but 
not to bronchial hyperresponsiveness or mild asthma 43. Furthermore, variations 
in the gene for T cell immunoglobulin mucin (TIM)-1, but not TIM-3, were found to 
contribute to asthma susceptibility in an African-American population 44. 
Variations in chemokine genes have also been associated with allergen 
susceptibility, as in the case of the haplotype block encoding several CXC 
chemokines 45. Based on these findings, it seems that genetic predisposition can 
influence an individual’s atopic status. It should however be kept in mind that this 
higher susceptibility is often of limited magnitude and that each variant is only 
found in minor fractions of patients. Furthermore, it does not explain the 
increasing prevalence of allergic disease. 
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Apart from genetic factors, a major factor that has been found responsible 
for the drastic increase in the prevalence of allergy in western society is our 
changing environment. The rapid industrialisation in the western world during the 
second half of the last century has brought along polluting substances, such as 
diesel exhaust particles, nitrogen oxide, ozone and tobacco smoke, which might 
be associated with the exacerbation and severity of asthma 46. However, their 
role in the induction of allergy remains controversial.  
In contrast to the outside milieu, our homes and living areas have become 
cleaner and more devoid of microbes during the last few decades. The original 
hygiene hypothesis suggested that a decreased microbial exposure early in life 
leads to the failure of the immune response to shift from a T helper (Th)2 cell-
dominated to a Th1 cell response. A widely used example of the effects of the 
living environment during childhood on the development of allergies is that of 
farmers’ children. Multiple studies, including a very elaborate one among over 
700 children in Finland 47, have shown a significantly lower incidence of allergy in 
children growing up on a farm, compared to those growing up in an urban 
environment. This remarkable difference is often attributed to the higher microbial 
load encountered on the farm. Other observations related to microbial infection 
early in life include the increased risk of childhood atopy after the use of 
antibiotics and the negative correlation with fever episodes during childhood 48, 49.  
These recent findings on the influences of our changing life style, although in 
some cases not more than suggestive, support the hygiene hypothesis and 
would indeed help explain the increase of Th2-related diseases, such as allergy, 
during the past decades. However, the simultaneous rise of Th1-related 
autoimmune diseases such as Crohn’s disease 50 and type 1 diabetes 51 during 
this same period remains to be explained. Therefore, one might suggest that 
reduced microbial exposure does not result in a dysbalance between Th1 and 
Th2 cells, but rather results in the aberrant expression of both subsets of T cells. 
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5.3.1 Atopic dermatitis 
 
Atopic dermatitis (AD) is one of the most frequent inflammatory skin diseases in 
the western world. AD is generally characterised by severe pruritus (itchiness), 
eczematous lesions, elevated total serum IgE, and specific IgE to aeroallergens, 
food allergens, auto-antigens and bacterial superantigens. In 1980, Hanifin and 
Rajka established diagnostic criteria, which are still used in clinical practice today 
52. A task force of the European Academy of Allergology and Clinical Immunology 
(EAACI) proposed a new nomenclature in 2003 53, but the new term atopic 
eczema (AE) has not been universally adopted. 
Although termed atopic, AD is not always associated with elevated serum 
IgE or specific IgE. Depending on populations and criteria, different studies have 
reported this to be the case in 10% to 45% of all AD patients 54. Therefore, AD is 
often divided into two different categories:  
1) The extrinsic or allergic form (EAD) is characterised by the elevation of 
total serum IgE levels. EAD might involve only the skin, but is often accompanied 
by comparable inflammation of the lung and nasal mucosa 55. About half of all 
individuals diagnosed with EAD also develop asthma and two-thirds develop 
allergic rhinitis. The cutaneous manifestations of EAD often begin in early 
childhood and are followed by IgE-mediated sensitisation to food allergens and 
the subsequent development of hypersensitivity to inhaled allergens. This 
development of IgE-mediated diseases throughout life is also known as the 
atopic march.  
2) The intrinsic or non-allergic form (IAD) shows normal total IgE serum 
levels and has negative serum levels of allergen-specific IgE 54. This subtype of 
AD is further characterised by a similar clinical phenotype to EAD and negative 
type 1 skin hypersensitivity to food allergens and aeroallergens. 
Despite these differences, the tissue injury in both forms seems to result 
from a common immunological mechanism (Figure 1). In both EAD and IAD, T 
cells activate B cells upon allergen recognition. In EAD this leads to IgE 
production, while in IAD IgG is produced 56. Activated Th2 cells upregulate the 
 26 
expression of cutaneous lymphocyte-associated antigen (CLA), the homing 
receptor involved in selective migration of T cells to the skin. In the dermal layer 
of the skin, these T cells subsequently upregulate the secretion of interferon-! 
(IFN-!) as well as the expression of the death receptor Fas and its ligand. This is 
induced through the local production of IL-12 and IL-18 by resident Langerhans’ 
cells, epidermal dendritic cells (EDC) and keratinocytes and gives the T cells a 
Th0/Th1 phenotype 57-59. Accordingly, T cells from draining lymphatic vessels of 
the skin, which represent de-homing effector T cells, express CLA and elevated 
levels of IFN-! 60. The T cells themselves are protected from apoptosis by 
cytokines and contact with the extracellular matrix (ECM) 61, although they 
express both Fas and FasL. Contact with the ECM has been shown to be 
essential for the survival of anchorage-dependent cells, but also appears to 
rescue T cells (which are not anchorage-dependent) from apoptosis. 
Furthermore, the common ! chain shared by several cytokine receptors is an 
essential signalling component for T cell survival 62. While T cells are protected 
from apoptosis, IFN-! and FasL cooperate to induce the major tissue injury event 
in AD, the apoptosis of keratinocytes. In asthma, a similar event leads to 
shedding of the epithelium, but in AD, keratinocyte apoptosis leads to the 
formation of spongiosis in the epidermal layer. It seems likely that keratinocyte 
stem cells located at the basal membrane are protected from T-cell-induced 
apoptosis due to strong anti-apoptotic signals from dermal fibrocytes and ECM 
proteins 63. 
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Figure 1. Immune effector mechanisms in extrinsic (EAD) and intrinsic (IAD) 
atopic dermatitis. In the peripheral blood of EAD patients CLA+CD45RO+ T cells are 
activated and the Th1 cells in particular undergo Fas-mediated activation-induced cell 
death (AICD). In contrast, T cells infiltrating the skin do not go into apoptosis and are 
saved by cytokines and by contact with the ECM. These T cells show elevated levels of 
IFN-!, which induces apoptosis of keratinocytes. In EAD, T cells in the skin secrete IL-5 
and IL-13, which prolongs eosinophil survival. In IAD, no IgE, but IgG against allergens 
is found in the circulation. Langerhans’ cells (LC) and epidermal dendritic cells (EDC) 
express high levels of Fc$RI in EAD. From Akdis CA and Akdis M, Clin. Exp. Allergy. 
2003; 33:1618-21 
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5.4 T cell regulation in health and disease 
 
 
5.4.1 T regulatory cells and the control of disease  
 
Numerous animal and human studies have shown that Treg cells can actively 
suppress the development of autoimmune disease and immunity against 
alloantigens. Sakaguchi et al. showed for first time that depletion of regulatory T 
cells from mice led to the development of autoimmune disease 64. Co-transfer of 
CD4+CD25+ Treg cells together with effector, disease-causing, T cells prevented 
mice from developing multiple experimentally induced autoimmune diseases 
such as colitis, gastritis, type 1 diabetes and thyroiditis 29, 65-67. In human studies, 
the role of regulatory T cells is mostly demonstrated by a lower frequency or 
activity of Treg cells compared to unaffected individuals. In multiple sclerosis, for 
example, CD4+CD25+ Treg cells from patients have a markedly reduced 
suppressive capacity compared to healthy individuals 68. Patients with chronic 
graft-versus-host disease (GVHD) show reduced numbers of CD4+CD25+ Treg 
cells compared to transplantation patients without GVHD 69. Equally, adoptive 
transfer of donor CD4+CD25+ Treg cells after haematopoietic cell transplantation 
promoted engraftment and tolerance in a mouse model of GVHD 70. CD4+CD25+ 
Treg cells activated by allogeneic APCs have been found to induce long term 
tolerance to bone marrow grafts, but simultaneous rejection of third-party bone 
marrow still occurred, indicating that in vivo CD4+CD25+ Treg cells work antigen-
specifically 71. Somerset et al. showed an increase in circulating maternal 
CD4+CD25+ Treg cells during early pregnancy 72. Polanczyk et al. reported that 
oestrogen augments FoxP3 expression by CD4+ T cells, suggesting that 
oestrogen aids in the formation of CD4+CD25+ Treg cells, which can suppress 
allogenic immune responses against the growing foetus 73. In concordance with 
these observations, cases of miscarriage and spontaneous abortion show a low 
number of circulating CD4+CD25+ Treg cells, suggesting a role for these in 
successful pregnancy 74.  
 29 
Although Treg cells obviously have a benign regulatory role in many 
conditions, immune suppression can also lead to serious illness. Already twenty-
five years ago, it was first recognised that the adoptive transfer of tumour-
reactive T cells was only beneficial in T cell-deficient mice, and not in 
immunocompetent animals, suggesting a presence of regulatory cells in tumour-
bearing individuals 75.  Several studies have since demonstrated an increased 
immune response against tumours after depletion of CD4+CD25+ Treg cells 76, 77. 
An upregulation in the number of circulating tumour antigen-specific CD4+CD25+ 
Treg cells has been shown in human studies of various forms of cancer 78.  
The long-term persistence of pathogens in a host is equally associated 
with the presence of antigen-specific CD4+CD25+ Treg cells. In the case of the 
parasite Leishmania major, for example, CD4+CD25+ Treg cells accumulate in 
the dermis of the skin and suppress anti-parasite immune responses by effector 
T cells 79. Also in tuberculosis, increased levels of CD4+CD25+ Treg cells have 
been found at the site of infection and in the blood of patients, compared to 
healthy individuals 80. 
Even though Treg cells may play a destructive role in cancer and chronic 
infectious diseases81-86, clinical studies are required to demonstrate whether in 
vivo generation or adoptive transfer of Treg cells and/or their related suppressive 
cytokines can be used to alter the progression of allergy and asthma. The 
generation of Treg cells and the enhancement of their suppressive properties 
provide important targets not only for use in allergy and asthma, but also in 
transplantation- and autoimmunity. 
 
 
5.4.2 Allergen-specific immunotherapy 
 
Allergic disease generally persists lifelong, although examples of spontaneous 
remission of symptoms do exist. The most well known example is probably the 
“outgrowing” of childhood asthma. More than 20% of asthmatic children were 
found to be in complete remission by the age of 32-42, without ever undergoing 
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immunotherapy 87. Cow’s milk allergy is often outgrown rapidly and a short milk-
free period in children’s diet often suffices to change the immune response to 
milk antigens 88. Despite these remarkable observations, there is still great need 
for curative treatment of allergic disease. The only currently available therapy 
with long-lasting effect is allergen-specific immunotherapy (SIT). Allergen-SIT 
has been commonly used as a treatment for allergic diseases for almost a 
century. Although results tend to vary, many examples of successful allergen-
SIT exist. The success of the therapy depends on patient selection, the time of 
onset, accompanying diseases, the severity of atopic status, the way of 
administration, and the type of vaccine used.  
 
5.4.2.1. Conventional Immunotherapy 
Allergen-SIT commonly involves the intradermal injection of allergen extracts. 
Immunotherapy against insect venom allergies has become very common and 
many studies on successful allergen-SIT have been reported within this field. 
The adverse effects of the most common way of venom-SIT, with aqueous 
venom solutions, are however often a reason for patients to discontinue 
treatment. Conventional allergen-SIT has been performed for almost a century 
using various types of allergen extracts. Despite the long-lasting success of 
conventional immunotherapy, there is great need for vaccines with higher 
efficacy and safety. The allergen mixtures in use often contain toxic or non-
allergenic protein and can therefore cause adverse effects. Furthermore, 
allergen-SIT can induce new IgE reactions or in rare cases even anaphylaxis in 
response to allergens contained in the extract. A recent survey in North America 
investigated the number of fatalities as a result of allergen-specific 
immunotherapy between 1990 and 2001 89. Their approximation of 3.4 deaths 
per year in North America alone clearly demonstrates the need for improved 
allergen-SIT vaccination strategies.  
 
 31 
5.4.2.2. Novel Immunotherapeutic Strategies 
Several possibilities have been explored to comply with the need for novel, safer 
and more efficient, vaccination strategies. One approach is to use non-injection 
routes of administering allergen, such as oral immunotherapy, local bronchial 
immunotherapy, local nasal immunotherapy or sublingual immunotherapy. Oral 
administration (swallowing) of allergens has been used as a therapy since 1927. 
However, most non-injection routes of administration have not led to an 
adequate alteration of the immune response. Only sublingual therapy is still in 
clinical use today, with successful treatment reported in cases of allergic rhinitis 
and asthma 90. 
 Another strategy to improve allergen-SIT involves the vaccination with 
allergen-encoding DNA. Occasionally, experimental therapies with intradermal or 
intramuscular injection of allergen-encoding DNA have shown reduced levels of 
IgE, accompanied by a shift in allergen-specific T cell balance from Th2 to Th1 
91. A lack of potency of DNA vaccines in humans has been reported not only in 
allergen-specific DNA vaccines, but also in the fields of infectious disease and 
cancer 92.  
More studies have focused on the use of well-defined hypoallergenic 
peptides instead of the full natural allergen protein. The benefit of peptide 
immunotherapy (PIT) is based on the idea that short allergen peptides, either 
native sequences or altered peptide ligands with amino acid substitutions, still 
contain the epitopes for recognition by T cells, but without the possibility of IgE 
cross-linking which induces anaphylaxis 93. Successful PIT using exact T cell 
epitope peptides from the major allergen phospholipase A2 has been reported 
several years ago 94. Peptides that can be used for PIT have now been defined 
for various allergens, including the latex allergen Hev b 6.01, the cat allergen Fel 
d 1, the house dust mite allergen Der p 1 and birch pollen allergen Bet v 1 95-98. 
Vaccination with these peptides generally showed a reduced Th2 response and 
often an increase in the secretion of the immunosuppressive cytokine IL-10, 
suggesting a shift towards Tr1 cells. Since peptide vaccination does not induce 
an IgE response, the therapy is well tolerated by patients. These results suggest 
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that PIT might be a suitable way of allergen-SIT. One down point of PIT, 
however, might be a possible limited applicability, since not all patients will 
respond to the same peptides, due to the diversity of MHC class II-mediated 
antigen presentation. 
Another very recent development in the immunisation with allergens 
without inducing IgE responses is gaining attention. It uses the previous 
observation that IgE recognises the three-dimensional structure of allergens, 
while T cells recognise linear sequences 99. Kussebi et al. genetically engineered 
a fusion protein that contains T cell epitopes, but not B cell epitopes, of two 
major bee venom allergens, phospholipase A2 (PLA) and hyaluronidase 
100. 
Karamloo et al., with a similar approach, combined three major bee venom 
allergens, PLA, hyaluronidase and melittin 101.  Pre-treatment with either of the 
fusion proteins protected mice from IgE, IgG2a and IgG1 antibody responses to 
later immunisation, therefore suggesting the induction of allergen-specific 
tolerance. Another group has recently shown that a polypeptide of three 
recombinant grass pollen allergens, Bet v 1, Phl p 1 and Phl p5, had comparable 
protective effects 102. Human immunotherapy with a combination of five 
recombinant grass pollen allergens successfully led to the amelioration of clinical 
symptoms of allergic rhinitis, with a shift in the immune response from IgE to 
IgG4 and the induction of IL-10-secreting Treg cells 103. The wide applicability of 
fusions, hybrids and chimeras of allergens, which preserve T cell tolerance-
inducing capacity without IgE binding, make these a very promising tool for 
allergen-SIT as well as preventive allergy vaccination. 
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Figure 2. The role of Treg cells in immunotherapy.  Treg cells control the activation 
of both Th1 and Th2 cells. Furthermore, their cytokines IL-10 and TGF-# induce a shift 
from allergen-specific IgE towards IgG4 and IgA, respectively, and inhibit the maturation 
of dendritic cells. Also, their activation leads to a reduction in the cytokines required for 
the release of inflammatory mediators by various effector cells. Adapted from Verhagen 
J et al., Int. Rev. Immunol. 2005; 24:533-48 
 
 
5.4.2.3. Treg cells in allergen-specific immunotherapy 
The induction of peripheral T cell tolerance plays a crucial role in allergen- SIT 16, 
17, 20, 104. Mouse studies have shown protection from the development of 
allergen-induced Th2 responses after the application of in vitro engineered 
allergen-specific Treg cells 105. Similarly, the proliferative response to nickel of 
CD4+ T cells from healthy, nonallergic individuals was strongly augmented when 
Treg cells were depleted 106. Numerous studies in humans and mice have shown 
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an increase in regulatory T cells in peripheral blood during allergen-SIT. These 
do not only include increased numbers of CD4+CD25+ Treg cells, but also the 
levels of IL-10-secreting Tr1 cells have been shown to be upregulated during the 
course of therapy 84, 107. The suppressive actions of these Tregs could be 
blocked by the use of neutralising mAbs against IL-10 and TGF-# 84. The 
appearance of CD4+CD25+ Treg cells has been associated with the 
spontaneous remission of cow’s milk allergy 88. Furthermore, it has been shown 
that CD4+CD25+ Treg cells from atopic donors have a reduced capability to 
suppress the activation of CD4+CD25- effector T cells 108. 
A shift from Th2 to Th1 responses is sometimes reported in studies of 
allergen-SIT 90. Although Th1 cells counteract the effects of allergy-inducing Th2 
cells, a Th1 response against allergens is equally undesired. Furthermore, IFN-! 
is not required for induction of aerosol-induced IgE unresponsiveness, as shown 
in IFN-! knockout mice and wild-type mice treated with anti-IFN-! antibody, 
showing that there is no requirement for Th1 cells in successful allergen-SIT. 
Moreover, neither CD8+ T cells nor !% TCR T cells are essential for a reduction in 
IgE production 109, therefore further suggesting a major role for Treg cells. 
T cell tolerance is initiated by the autocrine action of IL-10 and TGF-#, 
which are produced in significant amounts by Treg cells 16, 17, 20. A phenomenon 
crucial for successful allergen-SIT is the shift in balance between IgE and IgG4. 
Although peripheral tolerance has been demonstrated in specific T cells, the 
capacity of B cells to produce specific IgE and IgG4 antibodies is not eliminated 
during allergen-SIT 104. In fact, during the early phase of treatment, specific 
serum levels of both isotypes increase. The increase of specific IgA and IgG4 in 
serum coincides with increased TGF-# and IL-10 respectively.  
Although IgE antibody levels and IgE-mediated skin sensitivity normally 
require several years of SIT to show a reduction, most patients are already 
protected against allergens at an early stage of allergen-SIT.  This is probably 
because suppressed B cells and Treg cells cannot sufficiently provide the 
cytokines that effector cells (mast cells, basophils and eosinophils) require for 
priming, survival and activity 110, 111.  Allergen-SIT efficiently modulates the mast 
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cell and basophil activation thresholds and decreases IgE-mediated histamine 
release 112, 113 
 
 
5.5 Treg cells: suppressor mechanisms in allergic 
inflammation. 
 
5.5.1 Surface molecules: CTLA-4, PD-1 and GITR 
 
CD4+CD25+ Treg cells appear to suppress effector T cells in a cell contact-
dependent manner in vitro 114. Three major surface molecules have been 
associated with the function and activity of CD4+CD25+ Treg cells. The first, 
CTLA-4, is a co-stimulatory receptor of the CD28 family and a negative regulator 
of T cell activation 115. CTLA-4 is consistently highly expressed on human and 
murine CD4+CD25+ Treg cells 27. Similarly, it has been reported that the 
suppressive capacity of CD4+CD25+ Treg cells strongly correlates with high 
levels of CTLA-4 expression, consistent with a role in the suppressive function of 
CD4+CD25+ Treg cells 116. CD4+CD25+ Treg cells from CTLA-4-deficient mice 
show an impaired suppressive capacity 117 and these animals develop a fatal 
lymphoproliferative disease 118. A convincing in vitro demonstration of a direct 
functional role of CTLA-4 in Treg-mediated suppression, however, remains. 
CTLA-4-mediated regulation of CD4+CD25+ Treg cells is most likely due to an 
effect on their suppressive function, be it either direct or via the production of a 
secondary inhibitor 27.  
Programmed death-1 (PD-1) is another receptor that negatively regulates 
T cell activation. Like CTLA-4, it is a member of the CD28 family of co-stimulation 
receptors, but it has its own set of B7 family ligands, PD-L1 and PD-L2. An 
inhibitory role for PD-1 has been suggested based on the development of 
autoimmune disease in PD-1-deficient mice 119. Treatment of mouse target T 
cells with anti-PD-L1 led to the requirement of higher ratios of CD4+CD25+ Treg 
cells to suppress T cell activation 120. 
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Alloantigen-specific CD4+CD25+ Treg cells abundantly express GITR 28. 
This acts as a negative regulator of CD4+CD25+ Treg cell suppression, since 
binding of GITR by soluble GITR ligand leads to abrogation of the natural anergic 
state of the cell 121. It may therefore be a target for immunotherapy in cases of 
excessive CD4+CD25+ Treg cell function, as in cancer or chronic infection. 
 
 
5.5.2 Interleukin-10 
 
Studies have shown lower levels of IL-10 in the bronchoalveolar-lavage fluid of 
asthmatic patients than in healthy controls, and a lower production of IL-10 
mRNA in T cells of asthmatic children than of healthy children 122, 123.  These 
findings indicate that an increase in IL-10 production might lead to a decrease in 
allergic reactions. Reactivation of tolerised T cells can result in the distinct 
production of either Th1 or Th2 cytokine profiles depending on cytokines present 
in the tissue microenvironment 104. Antigen presentation to anergic T cells in the 
presence of IL-2 or IL-15 fully restores their ability to secrete IFN-!, but not IL-4. 
IL-15 is secreted by APC and many tissue cells and may therefore act to recover 
Th1 cells, but not Th2 cells, after allergen-SIT. Furthermore, IL-10 has been 
reported to block the B7/CD28 costimulatory pathway. As a result of this, IL-2 
produced in the microenvironment of peripheral tissues can restore allergen-
specific T cell activation, without the induction of IL-5 production. These findings 
suggest that IL-10, in combination with microenvironmental factors, can deviate 
the immune response against allergen from a Th2 to a Th1 biased mechanism. 
In the early stages of allergen-SIT, serum IgE levels do not immediately 
show a marked decline, but the increase in antigen-specific IgG4 is more striking 
and the ratio of specific IgE to IgG4 decreases by 10- to 100-fold 17. A similar 
change in specific isotype ratio was observed in SIT of various allergies. 
Meanwhile, IL-10 is induced and progressively secreted during SIT and appears 
to counter-regulate antigen-specific IgE and IgG4 antibody synthesis 16. IL-10 
has two major effects on B cells, which could result in the shift in balance as 
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observed. When added to PBMC during the first 3 days of in vitro culture, IL-10 
decreases $ transcript expression, and therefore production of IgE. However, 
when added to already committed B cells, IL-10 induces further upregulation of 
IgE production. Furthermore, IL-10 enhances !4 transcript expression and IgG4 
production induced by IL-4 124. Although IL-10 is not a switch factor for IgG4, it 
may augment IgG4 production by favouring the differentiation/activation of IgG4-
secreting cells or by enhancing the IL-4-induced class switching.  
The molecular mechanisms of T cell suppression by IL-10 have been 
investigated intensively.  IL-10 has been found to inhibit the proliferative T cell 
response in PBMC to various antigens, and the superantigen staphylococcal 
enterotoxin B 125. IL-10 does not affect the proliferative responses of anti-CD3-
stimulated T cells, but significantly inhibits the anti-CD28-induced proliferation. 
The investigation of triggered TCRs on T cells demonstrated the requirement for 
co-stimulation in T cell activation and its relation to the number of triggered TCRs 
125. T cells stimulated with variable concentrations of anti-CD3 mAb, and a 
constant amount of anti-CD28 showed that low numbers of triggered TCRs 
required CD28 co-stimulation and that only this co-stimulatory effect could be 
inhibited by IL-10. The stimulation of CD28 by specific monoclonal antibodies 
induces tyrosine phosphorylation of the cytoplasmic domain of the receptor.  
Ligation of IL-10 receptor (IL-10R) at the time of mAb stimulation inhibits the 
tyrosine phosphorylation of CD28 within minutes 125, 126.  The inhibitory effect of 
IL-10 appears to be specific for the co-stimulation pathways, as IL-10 does not 
affect ZAP-70 tyrosine phosphorylation stimulated by CD3 cross-linking 125.  As a 
consecutive event for signal transduction, phosphatidylinositol 3-kinase (PI3-K) 
binds to tyrosine phosphorylated co-stimulatory molecules by its p85 subunit. 
This association between co-stimulatory receptors and the PI3-K p85 subunit is 
inhibited by IL-10. IL-10 exerts its biological functions through the activation of 
Jak1 and Tyk2, the members of the receptor-associated Janus tyrosine kinases 
family and Stat1 and Stat3, and in certain cells Stat5 127.  Previous studies 
demonstrated that IL-10 does not only inhibit T cells, it is also a potent inhibitor of 
activated monocytes and macrophages 128.  Since monocytes and macrophages 
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do not express CD28, the inhibitory impact of IL-10 is likely to occur through 
other mechanisms in non-T cells.  In monocytes, IL-10 was shown to induce 
expression of the suppressor of the cytokine-signalling-3 (SOCS3) gene that may 
play a role in the inhibition of IFN-induced tyrosine phosphorylation of Stat1 129.  
Treg-derived IL-10 can have many other effects on the immune response, 
as well. The presence of IL-10 during maturation of DC can inhibit their full 
maturation, leading to decreased expression of MHC class II and several 
adhesion and co-stimulatory molecules. This results in the long lasting induction 
of tolerance in both Th1 and Th2 cells. In addition, IL-10 has been shown to 
reduce pro-inflammatory cytokine release from mast cells 130, down-regulate 
eosinophil function and activity, and suppress IL-5 production by resting human 
Th0 and Th2 cells 131.  
 
 
5.5.3 Transforming growth factor-#  (TGF-#) 
 
The role of TGF-# in the control of atopic disease has long been unclear, but is 
now gradually being unveiled. TGF-#-deficient mice have been demonstrated to 
show a higher susceptibility to asthma-like lung inflammation than their healthy 
counterparts 132. Furthermore, mice deficient in the transcription factor RUNX3 (a 
major mediator of TGF-# signalling) also show the spontaneous development of 
asthma-like symptoms 133. A mouse model of food allergy showed a significant 
reduction of secreted IgA antibodies in the gut. The recovery of this was 
correlated to the local production of TGF-# 134.  
Several reports have shown the importance of TGF-# in the induction and 
functioning of CD4+CD25+ Treg cells. CD4+CD25+ Treg cells not only express 
surface membrane-bound TGF-# in its latent form 135, but also express TGF-# in 
its active configuration on the cell surface 136. One animal model showed that 
CD4+CD25+ Treg cells from wild-type mice, but not those from mice with 
impaired TGF-# signalling could suppress colitis in wild-type mice 137. They 
further demonstrated that TGF-# promotes the expansion of CD4+CD25+ Treg 
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cells. Marie et al. 138 also showed that TGF-# maintains the FoxP3 expression of 
CD4+CD25+ Treg cells. In a model of autoimmune diabetes, it was shown that 
the onset of diabetes was slowed down by TGF-#-dependent CD4+CD25+ Treg 
cells, but also that a progressive resistance to TGF-#-mediated suppression 
played a role 139. Furthermore, experimental tracheal eosinophilia was inhibited 
by the induction of TGF-#-secreting CD4+ T cells 140. 
Less is known about the molecular mechanisms behind TGF-#-mediated 
suppression in allergen-SIT. High levels of TGF-# have been demonstrated to 
downregulate the expression of Fc$RI on Langerhans cells 141, leading to 
reduced IgE-mediated allergen presentation. Furthermore, it has been shown 
that the increased allergic inflammation seen after blocking CTLA-4 is clearly 
associated with decreased TGF-# levels within the bronchoalveolar-lavage fluid 
142. Finally, a link has been suggested between TGF-# and the induction of an 
IgA-dominated antibody response in mice 134. 
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6. Results 
 
6.1 Absence of T regulatory cell expression and function in 
atopic dermatitis skin.  
 
J allergy Clin Immunol., 2006. 117: 176-183 
 
Absence of T-regulatory cell expression and
function in atopic dermatitis skin
Johan Verhagen, MSc,a Mu¨beccel Akdis, MD, PhD,a Claudia Traidl-Hoffmann, MD,b
Peter Schmid-Grendelmeier, MD,c DirkJan Hijnen, MD,d Edward F. Knol, PhD,d
Heidrun Behrendt, MD,b Kurt Blaser, PhD,a and Cezmi A. Akdis, MDa Davos Platz
and Zurich, Switzerland, Munich, Germany, and Utrecht, The Netherlands
Background: The role of regulatory T cells has been widely
reported in the suppression of T-cell activation. A dysfunction
in CD41CD251 T-regulatory cell–specific transcription factor
FoxP3 leads to immune dysregulation, polyendocrinopathy,
enteropathy X-linked syndrome, often associated with atopic
dermatitis. Increasing the number and activity of regulatory
T cells in affected organs has been suggested as a remedy in
various inflammatory diseases, including allergy.
Objective: To determine the presence and function of
regulatory T cells in atopic dermatitis.
Methods: Immunohistochemistry of lesional atopic dermatitis
skin and control skin conditions was used to demonstrate
regulatory cells and cytokines in situ. The role of effector and
regulatory T cells as well as their specific cytokines in apoptosis
in human keratinocyte cultures and artificial skin equivalents
was investigated.
Results: Human T-regulatory type 1 cells, their suppressive
cytokines, IL-10 and TGF-b, as well as receptors for these
cytokines were significantly expressed, whereas
CD41CD251FoxP31 T-regulatory cells were not found in
lesional and atopy patch test atopic dermatitis or psoriasis skin.
Both subsets of regulatory T cells suppress the allergen-specific
activation of TH1 and TH2 cells. In coculture and artificial skin
equivalent experiments, subsets of T-regulatory cells neither
induced keratinocyte death nor suppressed apoptosis induced
by skin T cells, TH1 cells, IFN-g, or TNF-a.
Conclusion: A dysregulation of disease-causing effector T cells
is observed in atopic dermatitis lesions, in association with an
impaired CD41CD251FoxP31 T-cell infiltration, despite the
expression of type 1 regulatory cells in the dermis. (J Allergy
Clin Immunol 2006;117:176-83.)
Key words: Regulatory T cell, atopic dermatitis, apoptosis, suppres-
sion, regulation, skin, human, inflammation
Atopic dermatitis (AD) is a chronic relapsing skin
disorder with an interplay of migrating lymphocytes and
epidermal keratinocytes (KC).1,2 Lesional AD skin is his-
tologically characterized by dermal mononuclear infiltra-
tion and spongiosis in the epidermis. At the initial stages
of inflammation, TH2 cells migrate to the dermis, where
they acquire a TH0/TH1 phenotype under the influence
of IL-12, produced by antigen-presenting cells or acti-
vated keratinocytes.3-5 These TH0/TH1 cells are character-
ized by the expression of Fas ligand (FasL) and secretion
of significant amounts of the effector cytokines TNF-a
and IFN-g.2,4,5 The secreted IFN-g induces apoptosis
of keratinocytes, leading eventually to the eczematous
lesions characteristic of AD.6,7 In response, keratinocytes
upregulate the production of IFN-g–inducible chemo-
kines,8 which in turn promotes the further infiltration of
T cells into the epidermis, thereby augmenting the severity
of inflammation and keratinocyte apoptosis.
After their initial discovery in the early 1970s, the
concept of T-regulatory (Treg) cell–mediated immune
suppression has been extensively explored. Two main
groups of Treg cells have been defined. One comprises
the natural Treg cells, which are characterized by their
CD41CD251 phenotype. These cells have been sug-
gested to develop under the control of the transcription
factor FoxP3.9 The other group of Treg cells, the adaptive
Treg or T-regulatory type 1 (Tr1), are characterized by the
secretion of high levels of IL-10with orwithout TGF-b.10-12
They develop in the periphery under the influence of pre-
sumably immature dendritic cells13 and/or the presence of
IL-10 and TGF-b, but also immunosuppressive drugs like
glucocorticoids and vitamin D3,14 and operate in a
cytokine-mediated manner.
Most research on the inhibitory capacities of Treg cells
has focused on their ability to suppress proliferation of
effector T cells. It has been tempting to speculate that
migration of increased numbers of Treg cells to the
inflammation area, or the induction of their local prolif-
eration, might be beneficial in the treatment of several
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HDM: House dust mite
NAD: Nonallergic type of dermatitis
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inflammatory diseases, including allergy, autoimmunity,
and transplantation rejection. Accordingly, we investi-
gated the presence of Treg cells and their cytokines IL-10
and TGF-b, as well as their potential to suppress T-cell
effector functions in AD skin. Here, we show that IL-10–
secreting Tr1 cells, but not FoxP31CD41CD251 T cells,
infiltrate lesional AD skin, demonstrating an imbalance in
T-cell regulation in the affected organ.
METHODS
Subjects
PBMCs were isolated from peripheral blood of 15 healthy
volunteers or patients with AD (aged 19-45 years) hypersensitive to
house dust mite (HDM) or birch pollen allergens and then purified or
cultured to provide the various types of T cells used in this study.
Twenty-four–hour positive atopy patch test (APT) biopsies were
taken of 3 patients with AD at the UniversityMedical Center Utrecht,
The Netherlands, as previously described.15 Three psoriasis biopsies
were obtained from the ZAUM-Center for Allergy and Environment,
Munich, Germany. Lesional skin biopsies were obtained from 3
patients with allergic contact dermatitis and 8 patients with AD
diagnosed according to standard criteria16 at the allergy unit of the de-
partment of dermatology, University of Zurich. Patients with AD and
nonallergic form of dermatitis (NAD)17 were included in the study.
They did not receive any systemic therapy for at least 2 weeks before
taking the biopsy. All studies were approved by the ethical commis-
sions of the Canton of Graubunden, Switzerland, the Zurich
University, Switzerland, the ZAUM, Munich, Germany, or the
University Medical Center Utrecht, The Netherlands.
Purification and in vitro differentiation
of T-cell subsets
Cytokine-secreting cells. PBMCs were isolated by Ficoll
(Biochrom, Berlin, Germany) density gradient centrifugation of
peripheral venous blood. Cells were washed 3 times and resuspended
in RPMI 1640 medium supplemented as described.12 Cells, 2.5 3
107, were stimulated with 0.3 mmol/L Der p 1 in 5 mL medium in
6-well plates (Corning-Costar Corp, Cambridge, United Kingdom).
Secreting T cells were purified by immunomagnetic separation using
the cytokine-secretion assay (AutoMacs; Miltenyi Biotec, Bergish
Gladbach, Germany) for IL-4, IL-10, or IFN-g as previously de-
scribed.12 Purified IL-4–secreting cells, IL-10–secreting cells, and
IFN-g–secreting cells were stimulated in complete culture medium
with 1 nmol/L doses of growth factors: IL-2 (Roche, Basel,
Switzerland) and IL-4 (Novartis, Basel, Switzerland), IL-2 and IL-
15 (Peprotech, London, United Kingdom), and IL-2, respectively,
and the following combination of mAbs to T-cell surface molecules:
anti-CD2 (4B2 and 6G4, each 0.5 mg/mL), anti-CD3 (0.5 mg/mL),
and anti-CD28 (0.5 mg/mL; all from CLB, Amsterdam, The
Netherlands). Their cytokine profiles have been previously reported
as TH2-like, Tr1-like, and TH1-like cells, respectively.
12
CD41CD251 T cells. CD41CD251 T cells were purified from
PBMCs of healthy donors by using the CD41CD251 regulatory
T-cell isolation reagents (Miltenyi Biotec).18 The expression of
FoxP3 on CD41CD251 T cells was significantly higher than on
CD41CD252 T cells, as previously reported.19 Purified CD41CD251
T cells were cultured for 18 hours in complete RPMI 1640 medium
containing IL-2 before being used in experiments.
TH1 cells. CD45RA
1 T cells were purified by depletion of
PBMCs using Pan T-cell isolation reagents (Miltenyi Biotec) and
anti-CD45RO labeled microbeads (Miltenyi Biotec). Naive T cells
(1 3 105 cells in 500 mL complete RPMI 1640, in 48-well plates;
Corning-Costar Corp) were cultured with IL-2 (50 ng/mL), IL-12
(25 ng/mL), anti-CD2/3/28 mAb, and anti–IL-4 mAb (10 mg/mL)
for 12 days to generate TH1 cells.
20
AD skin–derived T cells. T cells from the epidermis of lesional
biopsies of patients with AD were isolated as previously described.5
FoxP3 mRNA expression was analyzed as previously described.19
Keratinocyte cultures
Primary human keratinocytes (pooled normal human epi-
dermal keratinocytes from neonatal skin) were purchased from
BioWhittaker, Verviers, Belgium; PromoCell GmbH, Heidelberg,
Germany; or Invitrogen, Basel, Switzerland, and grown in fully
supplemented keratinocyte growth medium (KGM-2 bullet kit,
BioWhittaker). During experiments, hydrocortisone was left out of
the medium. Immortalized human HaCaT keratinocytes (a gift from
Prof Dr N. E. Fusenig, Heidelberg, Germany) were grown in com-
plete RPMI 1640 medium.
T-cell–keratinocyte cocultures
Keratinocytes were first seeded into 48-well or 96-well plates
(Corning-Costar Corp) and were incubated to allow attachment and
formation of a 75% to 90% confluent monolayer. After refreshing the
medium, cytokines IFN-g (Peprotech), soluble Fas ligand (Alexis
Corp, Lausen, Switzerland), TNF-a (Alexis Corp; all 10 ng/mL), IL-
10 (20 ng/mL; Peprotech), and TGF-b (2 ng/mL; R&D Systems Inc,
Abingdon, United Kingdom) were used in different combinations.
IL-10 and TGF-bwere added at least 2 hours before if combinedwith
other cells and/or cytokines. In cocultures with keratinocytes, T cells
were incubated for only 24 hours and then washed away. If effector
and IL-10–secreting Tr1 or CD41CD251 T cells were combined,
regulatory cells were added at least 2 hours earlier. Of each type of
T cell, 2.5 to 5 3 104 (96-well or 48-well plate, respectively) were
used per well.
Artificial skin equivalents
Skin equivalents were cultured on dead de-epidermized dermis
from human foreskin. A total of 4 3 105 third passage primary hu-
man keratinocytes were seeded onto the de-epidermized dermis and
grown in an air-fluid interface for 10 days in modified Greens me-
dium.21 Fully differentiated artificial skin equivalents were grown
for 4 days in a transwell system, while combinations of IFN-g,
soluble Fas ligand (sFasL), IL-10, and TGF-b were added directly
to the medium below the insert. After 4 days, the skin pieces were
snap-frozen in liquid nitrogen and embedded in Tissue-Tek opti-
mal cutting temperature compound (Sakura Finetek Europe BV,
Zoeterwoude, The Netherlands).
Viability and apoptosis detection
Keratinocyte viability was evaluated by means of ethidium
bromide (25 mmol/L; Sigma Chemical Co, St Louis, Mo) exclu-
sion and flow cytometry (EPICS XL-MCL flow cytometer; Coulter
Corp, Hialeah, Fla). Hoechst staining was performed according to
Norris et al22 on cytospin samples and frozen sections of artificial
skin equivalents. Terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling staining was performed on frozen sections
of artificial skin equivalent by using the MEBSTAIN apoptosis kit
II (MBL, Naka-ku Nagoya, Japan). Stained samples were mounted
with Fluorescent Mounting Medium (DAKO, Glostrup, Denmark)
and subsequently evaluated under an ultraviolet microscope
(Axiovert 405M; Carl Zeiss AG, Feldbach, Switzerland).
Immunohistochemistry
Biopsy specimens were taken from lesions 3 to 6 days old and
positive 24-hour APT of patients with AD, and from normal skin
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of healthy individuals. Frozen sections were stained by using the
ready-to-use Vectastain Universal Elite Kit (Vector Laboratories,
Burlingame, Calif). Primary antibodies were antihuman IL-10, anti-
human TGFb1 (both R&DSystems Inc), antihuman IL-10R1, antihu-
man TGFbRI, anti-human TGFbRII (all Santa Cruz Biotechnology
Inc, Santa Cruz, Calif), antihuman FoxP3 ab10563 (Abcam,
Cambridge, United Kingdom), antihuman CD25 (BD Biosciences
Pharmingen, San Diego, Calif) and polyclonal rabbit or mouse IgG
(Santa Cruz Biotechnology) as isotype controls. FoxP3 peptide
ab14151 (0.125 mg/mL; Abcam) was used as a control to block
anti-FoxP3 binding.
Statistical analysis
All data are expressed as means 6 SDs. Statistical analysis was
performed by using the Student t test and Mann Whitney U test for
samples n < 6 (*P < .05).
RESULTS
Expression of IL-10 and TGF-b as well as their
receptors, but not FoxP3, in lesional AD skin
To investigate the expression and function of Treg
cells in AD, we looked at whether the Tr1 cell-specific
cytokines, IL-10 and TGF-b, or CD41CD251 Treg cell-
specific transcription factor FoxP3 are expressed in le-
sional AD skin. Despite the presence of large numbers
of CD251 cells (Fig 1, A), we did not detect any FoxP31
cells, neither in the dermal infiltrate of chronic lesional
AD skin nor in acutely inflamed skin 24 hours after
APT, psoriatic skin, or healthy skin (Fig 1, B). FoxP3
was detectable abundantly on T cells in the follicular
area of the tonsil, and on approximately 1% of infiltrating
T cells in allergic contact dermatitis skin by an exclusively
nuclear staining. The binding of FoxP3 antibody could
be blocked by preincubating the antibody with specific
FoxP3 peptide (Fig 1, C). Analysis of mRNA levels con-
firmed that T cells isolated from AD skin express very
low levels of FoxP3, comparable to CD41CD252 T cells.
CD41CD251 Treg cells express relatively high levels of
FoxP3 mRNA, which are upregulated on activation (Fig
1, D). Both IL-10 and TGF-b were abundantly present
throughout epidermal keratinocyte layers as well as in der-
mal mononuclear cell infiltrate of affected skin (Fig 2, A).
TGFbRI and TGFbRII were highly expressed in the
epidermis and dermis of affected skin, whereas IL-10R
was expressed in the whole epidermal layers, but only
on a few cells in the dermal infiltrate (Fig 2, B).
IL-4–secreting, IL-10–secreting, and
IFN-g–secreting T cells are present in
both AD and NAD skin lesions
Next, we isolated and characterized T cells from
lesional skin biopsies of 4 patients with AD and 4 patients
with NAD. Cytokine patterns determined by ELISA
FIG 1. A, CD25 expression in the dermis of AD, APT, and psoriasis
skin. B, FoxP3 staining in corresponding skin diseases (ACD, aller-
gic contact dermatitis) and human tonsil. Arrows indicate positive
cells. C, Blockage of FoxP3 staining with specific peptide. D, FoxP3
mRNA expression in skin T cells and blood CD41CD251 Treg cells
relative to CD41CD252 T cells (u.s., unstimulated; stim, anti-CD2,
anti-CD3, and anti-CD28 mAbs stimulation for 2 hour). Same
results obtained in 3 samples.
FIG 2. A, IL-10 and TGF-b expression in AD skin. B, TGFRI and
TGFRII were expressed throughout the skin, IL-10R almost exclu-
sively in the epidermis. Arrows indicate positive cells. Highlighted
areas magnified below. Scale bar: 50 mm. Similar results obtained
in 3 patients.
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showed a significant increase in IL-5 and IL-13 in AD. IL-
10, IFN-g, and IL-4 secretion did not differ significantly
between the 2 types of AD (Fig 3, A). In either type of AD,
both IFN-g as an effector cytokine and IL-10
as a regulatory cytokine were detectable. A quantitative
determination of IL-4–secreting, IL-10–secreting, and
IFN-g–secreting T cells was possible by capturing the se-
creted cytokine on the surface of the T cell. The majority
of T cells isolated from AD skin were IFN-g–secreting
cells. A considerable percentage of IL-10–secreting cells,
but only a minor fraction of IL-4–secreting cells, were
found among skin T cells (Fig 3, B).
Allergen-specific IL-10–secreting Tr1 cells and
CD41CD251 Treg cells inhibit activation of
allergen-specific effector T cells
To establish the immune regulatory capacity of the
IL-10–secreting Tr1-like cells used in this study, we
FIG 3. Cytokine profile of T cells isolated from AD skin. A, T cells
isolated from AD and NAD skin restimulated with anti-CD2, anti-
CD3, and anti-CD28 mAbs. Cytokines were measured after 72
hours in supernatants, by ELISA. *P < .005). B, Skin T cells were
stimulated for 48 hours with anti-CD2, anti-CD3, and anti-CD28
antibodies. IL-4–secreting, IL-10–secreting, and IFN-g–secreting
CD31 T cells were demonstrated.
FIG 4. Tr1 and CD41CD251 T cells suppress allergen-specific T
cells. Der p 1–specific IFN-g–secreting, IL-4–secreting, and IL-10–se-
creting T cells were purified from peripheral blood. IFN-g–secreting
(A) and IL-4–secreting (B) T cells were added to PBMCs and stimu-
lated with Der p 1 in the absence or presence of IL-10–secreting Tr1
cells. One experiment representative of 8 is shown. C, CD41CD251
T cells suppress the Der p 1–induced proliferation of PBMCs of
donors allergic to HDM (n 5 3). u.s., Unstimulated. [3H] Thymidine
(TdR) incorporation determined after 5 days. *P < .05.
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examined their effect on the antigen-specific activation of
IL-4–secreting TH2-like and IFN-g–secreting TH1-like T
cells. Freshly purified TH cells selected for their specific-
ity against the HDM allergen Der p 1 showed increased
proliferation upon encounter with this allergen when
added to autologous PBMCs (Fig 4, A and B). An equal
amount of IL-10–secreting Tr1 cells to that of IL-4–
secreting or IFN-g–secreting cells nearly abolished this
response. This shows that IL-10–secreting Tr1 cells can
suppress allergen-specific activation of both TH2-like
and TH1-like cells. Similarly, CD4
1CD251 T cells
showed significant suppression of Der p 1–specific prolif-
eration of PBMCs from donors allergic to HDM (Fig 4,C).
Tr1 cells, their cytokines IL-10 and TGF-b, and
CD41CD251 Treg cells do not suppress
T-cell–induced keratinocyte apoptosis
T-cell–induced keratinocyte apoptosis plays an essen-
tial role in the development of eczematous lesions in AD.
Accordingly, we investigated whether Tr1 cells or their
suppressive cytokines IL-10 and TGF-b can suppress skin
T-cell–induced, in vitro differentiated TH1 cell–induced,
or IFN-g and sFasL–induced keratinocyte apoptosis in co-
cultures and artificial skin equivalents. Keratinocyte death
induced by skin T cells did not show any difference
between T cells isolated from AD or NAD biopsies. In
both cases, keratinocyte death induced by preactivated
skin T cells was not prevented by the addition of IL-10–
secreting Tr1 cells in coculture (Fig 5, A). Moreover, skin
T-cell–induced keratinocyte death was not blocked by the
addition of IL-10 or TGF-b (Fig 5, B).
The suppressive capacity of IL-10–secreting Tr1 cells
on IL-12–driven TH1 cell–induced keratinocyte apoptosis
was further analyzed in cocultures with human keratino-
cytes. IL-10–secreting Tr1 cells did not affect keratinocyte
viability alone, nor did they suppress TH1 cell–induced
keratinocyte death in cocultures (Fig 5, C). Addition of
IL-10 or TGF-b to keratinocytes during coculture again
did not suppress TH1-induced keratinocyte death (Fig 5,
D). Bright, condensed, and fragmented staining of kera-
tinocyte nuclei with Hoechst 33342 dye, 3 days after co-
culture with TH1 cells, further confirmed these findings
FIG 5. IL-10, TGF-b, and Tr1 cells do not influence keratinocyte (KC)
apoptosis. A, Viability of KCs 3 days after coculture with T cells iso-
lated from AD or NAD skin. IL-10–secreting Tr1 cells were added in
equal amounts to skin T cells. B, IL-10 and TGF-b do not influence
skin T-cell–induced KC death. C, KCs cocultured with Tr1 cells and
TH1 cells. D, IL-10 and TGF-b do not influence TH1 cell–induced KC
death. E, Staining of KCs 3 days after coculture with TH1 cells and/
or IL-10–secreting Tr1 cells with Hoechst 33342. F, KCs stimulated
for 3 days with IFN-g, TNF-a, IL-10, and TGF-b. (A-F) One ex-
periment representative of 3 is shown. Viability determined by
ethidium bromide exclusion. G, Artificial skin equivalents were
cultured with IFN-g and sFasL for 4 days, in the presence or
absence of IL-10 (10 ng/mL) and TGF-b (2 ng/mL). *P < .05. TUNEL,
Terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling.
FIG 6. CD41CD251 Treg cells do not affect keratinocyte (KC) death
induced by (A) IFN-g and sFasL (72 hours), (B) in vitro–differenti-
ated TH1 cells (48 hours), or (C) CD4
1CD252 T cells, preactivated
for 48 hours. Viability was measured by ethidium bromide exclu-
sion 48 to 72 hours after coculture. Experiments were performed
at least twice in triplicate cultures. *P < .05.
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and suggested that cell death was in the form of apoptosis,
which was not inhibited by IL-10–secreting Tr1 cells
(Fig 5, E).
Because direct T-cell–keratinocyte contact is not es-
sential for the pathology of AD, we performed the same
experiments based solely on cytokines. Keratinocytes
were cultured with the effector cytokines IFN-g and
TNF-a. Again, a substantial reduction in the viability of
keratinocytes was observed, mainly after culture with
IFN-g and to a lesser extent with TNF-a after 3 days. As in
the experiments with TH1 cells, the induced keratinocyte
death was not suppressed by IL-10 and TGF-b (Fig 5,
F). Similar results were obtained with HaCaT and primary
human keratinocytes.
The differentiation status of keratinocytes was hypoth-
esized to play a role in the observations with monolayer
cell cultures. Accordingly, the effects of the aforemen-
tioned cytokines were studied in a model of artificial
skin equivalents in a 3-dimensional structure that in-
volves primary human keratinocytes, dermal fibrocytes,
and extracellular matrix proteins. IFN-g and sFasL
induced severe cell death throughout the epidermis of
skin equivalents after 4 days (Fig 5, G). Similar to mono-
layer keratinocyte cultures, IL-10 or TGF-b did not sup-
press the apoptosis of keratinocytes in artificial skin
equivalents.
A direct interaction of CD41CD251 Treg cells and
keratinocytes was investigated by the addition of
CD41CD251 Treg cells to TNF-a–stimulated or IFN-g–
stimulated keratinocytes. The reduced viability of kera-
tinocytes observed after 3 days was not affected by
CD41CD251 Treg cells, similar to the findings with
IL-10–secreting Tr1 cells (Fig 6, A). Like Tr1 cells,
CD41CD251 Treg cells did not induce keratinocyte
apoptosis. To assess whether CD41CD251 Treg cells
suppress TH1-induced or CD4
1CD25- T-cell–induced
keratinocyte apoptosis, CD41CD251 Treg cells were
added to a coculture of TH1 or CD4
1CD252 T cells with
keratinocytes. In both cases, CD41CD251 Treg cells did
not inhibit keratinocyte death (Fig 6, B and C).
DISCUSSION
During the last decade, a significant amount of data
has accumulated on the suppressive effects of Tr1 or
CD41CD251 T-regulatory cells in models of autoimmu-
nity, allergy, transplantation tolerance, tumor tolerance,
and chronic infections.12,23 The efficacy of various Treg
cell subsets in the suppression of inflammation has
tempted scientists to speculate that increasing Treg cell
numbers may suppress inflammation and tissue injury in
affected organs. In the current study, we show that
FoxP31CD251 T cells are not present in AD skin,
whereas Tr1 cells, their suppressive cytokines IL-10 and
TGF-b, and receptors for these cytokines are abundantly
expressed. Both CD41CD251 T regulatory cells and
Tr1 cells can efficiently suppress activation of TH1 and
TH2 cells stimulated with allergen/antigen. However, the
effector function of preactivated T cells, namely keratino-
cyte apoptosis, is not affected either by CD41CD251
T cells or Tr1 cells and their suppressive cytokines IL-10
and TGF-b.
One difficulty in comparing the results of different
studies with Treg cells is the variation in regulatory cell
types. The IL-10–secreting Tr1 cells used in this study
were selected for their allergen-induced IL-10 secretion as
previously described.12 CD41CD251 T cells were iso-
lated from peripheral blood of healthy and donors allergic
to HDM. Most studies with IL-10–secreting Tr1 cells
and CD41CD251 T cells have focused on their ability to
inhibit proliferation of responder cells. Here, we dem-
onstrate that IL-10–secreting Tr1 cells can inhibit the
allergen-specific proliferation of IL-4–secreting TH2 as
well as of IFN-g–secreting TH1 cells. In addition, a consid-
erable percentage of T cells isolated from lesional AD skin
are IL-10–secreting cells. Furthermore, we showed the
presence of Tr1 cytokines, IL-10 and TGF-b, and their re-
ceptors in biopsies of AD skin. Supporting these findings,
overexpression of IL-10 was previously described in
AD,24 and all isoforms of TGF-b have been described to
be expressed in nonaffected skin, with an upregulation
during wound repair.25
Previously, CD41CD251 Treg cells and CLA1CD41
CD251 T cells have been demonstrated to be elevated in
peripheral blood of patients with AD compared with
healthy controls or patients with asthma.26 Although we
found a high amount of CD251 cells in the dermal infil-
trate of AD skin, we did not detect any FoxP3 expression.
This shows that these CD251 cells present in the skin are
activated T cells and not regulatory CD41CD251 T cells.
Similarly, circulating CLA1CD41 or CD81 T cells have
been demonstrated to express CD25 highly and display
effector functions by inducing IgE production by B cells
and prolonged survival of eosinophils.26 Mutations in
the FoxP3 gene have previously been reported to play
a critical role in the onset of immune dysregulation,
polyendocrinopathy, enteropathy X-linked syndrome, an
X-linked recessive immunological disorder. This rare
disease is often associated with eczema (4 out of 5 patients
in 1 study) and high levels of IgE.27 Together, these data
suggest that there might be an essential role for
CD41CD251FoxP31 Treg cells in controlling inflamma-
tion of the skin, a system apparently malfunctioning in AD.
Both IL-10R and TGF-bR have been described in the
epidermis of healthy skin, with a marked upregulation
of the latter during wound repair.28,29 In contrast to pso-
riasis,28 IL-10R was abundantly expressed throughout
affected epidermis in AD. Although no effect of IL-10
on keratinocytes has previously been reported, this
expression of IL-10R suggests that there might be a role
for IL-10 in the control of keratinocyte death in AD.
Accordingly, we examined the role of IL-10–secreting
Tr1 and CD41CD251 Treg cells in the control of kerati-
nocyte apoptosis on both a cell-to-cell contact and a cyto-
kine-mediated level. We found that T cells isolated from
lesional skin of patients with AD induced apoptosis of ke-
ratinocytes, despite the presence of a considerable amount
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of IL-10–secreting Tr1 cells. The addition of exogenous
IL-10–secreting Tr1 cells isolated from peripheral blood
of healthy donors did not prevent the apoptosis of kerati-
nocytes in these cocultures. A defect in regulation has
been suggested as a determinant in the ongoing effector
functions of AD skin T cells. Superantigens, present in
the skin of more than 90% of patients with AD, can induce
strong proliferation of CD41 and CD81 T cells in the
skin.30 Strong binding of superantigens to the TCR in con-
junction with CD28 costimulation31 was shown to render
T cells insensitive to suppression by CD41CD251 Treg
cells32 and IL-10.33 Superantigens also abrogate immune
suppression by corticosteroids,34 which operate via the
induction of Treg cells19 This provides a possible explana-
tion for the absence of inhibition of skin T-cell–induced
keratinocyte apoptosis by Tr1 or CD41CD251 Treg cells.
To exclude this phenomenon, the same experiments were
repeated with Th1 cells and CD41CD252 T cells from
healthy donors. The apoptosis induction by these cell
types was comparable to that seen with skin T cells, but
Tr1 and CD41CD251 Treg cells did not induce keratino-
cyte apoptosis. Because an inhibitory effect might be
cell contact–independent and cytokine levels secreted by
T cells may vary, similar experiments were performed
with effector cytokines such as TNF-a and IFN-g and
suppressor cytokines like IL-10 and TGF-b. Again, no
inhibitory effect of IL-10 and TGF-b was seen on IFN-g–
induced or TNF-a–induced apoptosis.
In perspective, 4 distinct stages play an important role
in allergic inflammation of the skin. The first is the acti-
vation of T cells by allergens or superantigens, followed
by organ-selective homing, whereby cells are influenced
by the network of chemokines in the skin.2,35 The third
stage is classified by prolonged survival of inflammatory
cells within the inflamed skin and reactivation, by aller-
gens and/or superantigens. Finally, the effector role of
T cells in the skin is characterized by the induction of
keratinocyte apoptosis and development of spongiosis,
all of which are important factors in AD. Thus, regulatory
T cells of either Tr1 or CD41CD251 Treg phenotype can
suppress antigen-specific activation of T cells (stage 1 and
stage 3), but they cannot prevent activated effector T-cell–
induced keratinocyte apoptosis (stage 4). In addition,
taken together with AD and hyper-IgE in the phenotype
of immune dysregulation, polyendocrinopathy, enteropa-
thy X-linked syndrome, the absent expression
of CD41CD251FoxP31 Treg cells in AD and psoriasis
skin suggests a dysregulated control of inflammation,
particularly by natural Treg cells.
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6.2 Immune responses in healthy and allergic individuals 
are characterized by a fine balance between allergen-specific T 
regulatory 1 and T helper 2 cells. 
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Abstract
 
The mechanisms by which immune responses to nonpathogenic environmental antigens lead
to either allergy or nonharmful immunity are unknown. Single allergen-specific T cells constitute
a very small fraction of the whole CD4
 

 
 T cell repertoire and can be isolated from the peripheral
blood of humans according to their cytokine profile. Freshly purified interferon-
 

 
–, interleukin
(IL)-4–, and IL-10–producing allergen-specific CD4
 

 
 T cells display characteristics of T helper
cell (Th)1-, Th2-, and T regulatory (Tr)1–like cells, respectively. Tr1 cells consistently represent
the dominant subset specific for common environmental allergens in healthy individuals; in
contrast, there is a high frequency of allergen-specific IL-4–secreting T cells in allergic individuals.
Tr1 cells use multiple suppressive mechanisms, IL-10 and TGF-
 

 
 as secreted cytokines, and
cytotoxic T lymphocyte antigen 4 and programmed death 1 as surface molecules. Healthy and
allergic individuals exhibit all three allergen-specific subsets in different proportions, indicating
that a change in the dominant subset may lead to allergy development or recovery. Accord-
ingly, blocking the suppressor activity of Tr1 cells or increasing Th2 cell frequency enhances
allergen-specific Th2 cell activation ex vivo. These results indicate that the balance between
allergen-specific Tr1 cells and Th2 cells may be decisive in the development of allergy.
Key words: peripheral tolerance • allergens • suppression • interleukins • immune regulation
 
Introduction
 
The immune system must distinguish between innocuous
and pathological antigens to prevent unnecessary and self-
destructive immune responses (1, 2). A central finding from
experimental models and human studies shows that allergic
diseases are due to an aberrant immune response mediated
through a key effector cell, the Th type 2 cell and an asso-
ciated cytokine pattern including IL-4, IL-5, and IL-13 (3,
4). Therefore, the most pronounced findings with potential
relevance to allergy therapy are related directly to the con-
trol of these Th2 immune effectors. There is strong evi-
dence that peripheral T cell regulation plays a crucial role
in the control of harmful T cell responses. To avoid
chronic cell activation and inflammation against nonpatho-
genic antigens through ingestion and inhalation, the immune
system has developed efficient peripheral tolerance mecha-
nisms. Since the early 1970s (5), different subtypes of regu-
latory and suppressor cells and mechanisms that may play a
role in peripheral tolerance have been demonstrated, and their
biology has been the subject of intensive investigation (6–14).
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A great deal of uncertainty remains about differentiation
factors, antigen specificity, and mechanisms of action of T
regulatory (Tr) cells. Several types of Tr cells have been
described with a unique mechanism of action that varies
depending on the experimental model. Recent studies
have shown that Tr cells act as suppressor T cells that
down-regulate other effector T cells and inflammation
models in chronic infection, organ transplantation, and au-
toimmunity (10, 15–17). Studies on the immune response
to allergens provide well-defined models for understanding
the regulation and circumvention of antigen-specific T cell
responses. The symptoms of IgE-mediated allergy rhinitis,
conjunctivitis, and asthma can be ameliorated by the tem-
porary suppression of mediators and immune cells (such as
antihistamines and corticosteroids; reference 18). How-
ever, the only long-term solution for the treatment of al-
lergy is allergen-specific immunotherapy by the adminis-
tration of high doses of allergen or allergen peptides that
specifically target T cells over a long period of time (19,
20). Successful venom and aeroallergen immunotherapy
was found to be associated with the induction of peripheral
tolerance in T cells by generation of Tr cells that secrete
the suppressive cytokines IL-10 and TGF-
 

 
, suggesting
that generation of Tr1 cells might play a role in healthy
immune response (11, 21).
Studies on immune response to allergens in healthy indi-
viduals demonstrated that a peripheral T cell repertoire to
allergens exists that recognizes the same T cell epitopes as
allergic patients (22, 23). In the present work, we used a di-
rect approach by purification, characterization, and fre-
quency determination of allergen-activated T cells accord-
ing to their cytokine secretion profile. This enabled a
suitable human model to investigate how harmless envi-
ronmental proteins are recognized and tolerated by the
immune system. We showed that healthy and allergic
immune response to common environmental proteins is
characterized by a delicate balance in frequency of allergen-
specific Tr1 cells and allergen-specific Th2 cells.
 
Materials and Methods
 
Study Population. 
 
Heparinized peripheral blood samples from
31 healthy individuals (mean age, 36 yr) with no history of atopy
and 8 birch pollen and 9 house dust mite allergic patients, who
were diagnosed by positive skin test reactivity and high specific
IgE antibodies (
 

 
0.70 kU/l, Pharmacia Cap assay) were studied.
Total IgE levels of healthy individuals were 
 

 
88 U/ml, and aller-
gic individuals were between 92 and 298 U/ml. The study was
approved by the ethical commission of Davos, Switzerland.
 
Antigens. 
 
rBet v 1 of birch pollen (
 
Betula verrucosa
 
), rDer p 1
of house dust mite (
 
Dermatophagoides pteronyssinus
 
), rPyr c 5 of
pear (
 
Pyrus communis
 
), and rCor a 1 of hazelnut (
 
Corylus avellana
 
)
were used. rPyr c 5 and r Cor a 1 were provided by S. Vieths
and D. Lüttkopf (Paul Ehrlich Institute, Langen, Germany). All
of the allergens did not contain detectable amounts of LPS and
were 
 

 
99% pure. Purified protein derivative of 
 
Mycobacterium
bovis
 
 (PPD) was obtained from the Serum Institute, Copen-
hagen, Denmark. Tetanus toxoid was obtained from the Insti-
tute Berne, Switzerland.
 
Purification of Allergen-specific IL-4–, IFN-
 

 
–, and IL-10–secreting
Cells. 
 
PBMCs were isolated by Ficoll (Biochrom) density gra-
dient centrifugation of peripheral venous blood, and cells were
washed three times and resuspended in RPMI 1640 medium sup-
plemented as described previously (8). 2.5 
 

 
 10
 
7
 
 cells were stim-
ulated with 0.3 
 
	
 
M antigens in 5 ml of medium in six-well plates
in duplicates (Costar Corp.). After 12 h of stimulation in humidi-
fied 5% CO
 
2
 
, cells were harvested and labeled with 50 
 
	
 
g/ml
anti–IFN-
 

 
/CD45, anti–IL-4/CD45, or anti–IL-10/CD45 Ab–
Ab conjugates (Miltenyi Biotec) for 10 min at a concentration of
10
 
8
 
 cells/ml in ice-cold RPMI 1640 medium (24). The cells
were diluted with 37
 


 
C warm medium to a final concentration of
10
 
6
 
 cells/ml and allowed to secrete and capture the respective cy-
tokines for 45 min at 37
 


 
C. After capturing the secreted cyto-
kines on their surface, cells were centrifuged at 300 
 
g
 
 for 5 min at
4
 


 
C and resuspended at a concentration of 10
 
8
 
 cells/ml in ice-
cold buffer containing 0.5% BSA and 5 mM EDTA (both ob-
tained from Sigma-Aldrich) in PBS. The cells were stained with 5
 
	
 
g/ml PE-conjugated anti–IFN-
 

 
, anti–IL-10, or anti–IL-4 for
10 min at 4
 


 
C. The cells were washed and resuspended in 400 
 
	
 
l
BSA-EDTA PBS and magnetically labeled for 15 min at 4
 


 
C
with 100 
 
	
 
l of anti-PE microbeads. After washing, labeled cells
were purified by immunomagnetic separation (AutoMacs; Mil-
tenyi Biotec). The cells were counterstained by FITC-labeled anti-
CD4 and anti-CD8 mAb (Immunotech) and analyzed in a flow
cytometer (Epics XL; Beckman Coulter; Fig. S1). The purity of
allergen-specific CD4
 

 
 cytokine-secreting cells was between 88
and 96%. The frequency of allergen-stimulated and unstimulated
cells was calculated by dividing the number of purified cytokine-
secreting CD4
 

 
 T cells by the initial number of CD4
 

 
 T cells.
To obtain the frequency of allergen-specific, cytokine-secreting
T cells, the unstimulated cytokine-secreting CD4
 

 
 T cell fre-
quency was subtracted from allergen-stimulated cell number.
 
T Cell Cultures. 
 
The purified allergen-specific, cytokine-
secreting T cells were used immediately or expanded in the pres-
ence of 1 nM doses of growth factors (IL-2 for IFN-
 

 
–secreting
T cells; IL-2 and IL-4 for IL-4-secreting T cells; and IL-2 and IL-
15 for IL-10–secreting T cells; Novartis AG). Their cytokine
profile was determined both immediately after purification and
after in vitro expansion. Expanded IL-4–, IL-10–, and IFN-
 

 
–
producing cells were washed, and 5 
 

 
 10
 
5
 
 cells were restimulated
with a combination of mAbs to CD2, CD3, and CD28 mole-
cules (each 0.5 
 
	
 
g/ml; CLB) in 500 
 
	
 
l supplemented RPMI
1640 medium in 48-well plates for 3 d in triplicates. Supernatants
were harvested, and cytokines were determined by solid phase
sandwich ELISAs for IFN-
 

 
, IL-4, IL-5, IL-10, IL-13, and TGF-
 

 
as described previously (8, 21). Anti–IL-4 and anti–IFN-
 

 
 mAbs
were provided by C.H. Heusser (Novartis Pharmaceuticals,
Basel, Switzerland).
Allergen-specific T cell proliferative response was determined
by stimulation of 2 
 

 
 10
 
5
 
 PBMCs alone or together with ex-
panded or freshly purified allergen-specific, cytokine-secreting T
cells for 5 d with 0.3 
 
	
 
M of antigens in 200 
 
	
 
l of medium in 96-
well flat-bottom tissue culture plates in triplicates (25). Autolo-
gous 3,000 rad irradiated PBMCs were used as APCs. Cells were
pulsed with 1 
 
	
 
Ci/well [
 
3
 
H]thymidine (Dupont and NEN Life
Science Products), and incorporation of labeled nucleotide was
determined after 8 h in an LKB 
 

 
 plate reader (Wallac and Amer-
sham Biosciences). For polyclonal activation of T cells, plates
were coated for 2 h at 37
 


 
C with 10 
 
	
 
g/ml anti-CD3. IL-10 was
neutralized in cultures with 4 
 
	
 
g/ml anti–IL-10R mAb (pro-
vided by K. Moore, DNAX Research Institute, Palo Alto, CA;
reference 26). TGF-
 

 
 was neutralized in cultures with 100 ng/ml
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of recombinant human soluble TGF-
 

 
 receptor II/Fc chimeric
protein (R&D Systems; reference 21). Programmed death 1 (PD-1)
activity was neutralized in cultures with 5 
 
	
 
g/ml anti–human
PD-1 (Bioscience Insight Biotechnology Ltd.). CTL antigen 4
(CTLA-4) activity was neutralized with 5 
 
	
 
g/ml anti-CD152
F(ab)
 
2
 
 (Ancell and Qbiogene). The neutralizing activity of these
approaches was controlled in titrated doses. Rabbit IgG, rat IgG,
mouse IgG1, or BSA (Beckman Coulter) served as control.
 
Flow Cytometry, Immunohistology, and ELISPOT Assay. 
 
2.5 
 

 
10
 
4
 
 cells were stained with FITC-conjugated anti-CD25 mAb
together with anti–CD4-ECD, anti–CD152-PE (CTLA-4; BD
Biosciences), or anti–PD-1 (Bioscience Insight Biotechnology
Ltd.) for 30 min at 4
 


 
C. Stained cells were fixed in 2% parafor-
maldehyde. The controls were FITC, PE, or ECD-conjugated
mouse IgG1. For analysis of IL-10R, 5 
 

 
 10
 
4
 
 cells were stained
with 50 
 
	
 
g/ml of anti–IL-10
 

 
 mAb (DNAX Research Institute)
for 30 min and washed with 2% FCS containing PBS. FITC-
conjugated anti–rat Ig was the second Ab used for 30 min.
Intracellular cytokines were detected after anti-CD2, anti-
CD3, and anti-CD28 mAb stimulation for 12 h. 2 
 
	
 
M monensin
(Sigma-Aldrich) was added during the last 10 h (11). Intracyto-
plasmic cytokine profile of in vitro–expanded allergen-specific T
cells was determined as aforementioned. Labeled mAbs for cyto-
kines were obtained from BD Biosciences. Immune histology
was performed in cytospins of freshly purified cells by using anti–
human TGF-
 

 
RI, anti–human TGF-
 

 
RII, or rabbit IgG as iso-
type control (all obtained from Santa Cruz Biotechnology Inc.) as
described previously (27).
10
 
6
 
 cells/ml PBMCs from six healthy donors were stimulated
in 200 
 
	
 
l of medium 96-well flat bottom ELISPOT plates for
18 h (Euroclone Ltd.). Locally produced IL-4, IFN-
 

 
, and IL-10
were captured by specific mAb. After cell lysis, trapped cytokine
molecules were revealed by a secondary biotinylated detection an-
tibody, which is in turn recognized by streptavidin conjugated to
alkaline phosphatase. Colored “purple” spots developed after sub-
strate addition were determined (ImmunoSpot; Cellular Technol-
ogy Ltd.). The number of spots determined in triplicates of un-
stimulated wells was subtracted from 0.3 
 
	
 
M Der p 1–stimulated
wells. 18 h was found to be the optimal time for the determina-
tion of frequency of cytokine-secreting cells, as it is the time point
for highest cytokine secretion before T cell proliferation starts.
 
Quantitative Real-Time PCR. 
 
Immediately after purifica-
tion, antigen-specific, cytokine-secreting T cells were lysed with
RNeasy lysis buffer, and the RNA was isolated using the RNeasy
mini kit (QIAGEN) and eluted in 30 
 
	
 
l ddH
 
2
 
O. Reverse tran-
scription was performed with TaqMan
 
®
 
 reverse transcription re-
agents with random hexamers (Applied Biosystems). The PCR
primers and probes detecting elongation factor-1
 

 
 (EF-1
 

 
), IL-
10, TGF-
 

 
, IL-13, and IFN-
 

 
 were designed based on sequences
reported in GenBank. Primers used were as follows: EF-1
 

 
 for-
ward primer, 5
 

 
-CTGAACCATCCAGGCCAAAT-3
 

 
, EF-1
 

reverse primer, 5-GCCGTGTGGCAATCCAAT3; IL-13 for-
ward primer A, 5-GCCCTGGAATCCCTGATCA-3, IL-13
reverse primer A, 5-GCTCAGCATCCTCTGGGTCTT-3;
IFN- forward primer B, 5-TCTCGGAAACGATGAAAT-
ATACAAGTTAT-3, IFN- reverse primer B, 5-GTAACA-
GCCAAGAGAACCCAAAA-3; IL-10 forward primer, 5-
GGCGCTGTCATCGATTTCTT-3, IL-10 reverse primer, 5-
TTGGAGCTTATTAAAGGCATTCTTC-3; TGF-1 forward
primer, 5-AAATTGAGGGCTTTCGCCTTA-3, and TGF-1
reverse primer, 5-GAACCCGTTGATGTCCACTTG-3. cDNAs
were amplified using SYBR®-PCR mastermix (Applied Bio-
systems) according to the recommendations of the manufacturer
in a total volume of 25 	l in a sequence detection system (ABI
Figure 1. Allergen-specific IL-4-, IFN-–, and IL-10–
secreting T cells represent Th2-, Th1-, and Tr1-like
cells. (A) IL-10, IL-13, IFN-, and TGF- mRNA
were quantified by real-time PCR immediately after
isolation of Der p 1– or Bet v 1–specific, cytokine-
secreting T cells and their relative expression compared
with the housekeeping gene EF-1. The same results
were obtained in three independent experiments. (B) Bet
v 1–, Der p 1–, and Cor a 1–specific IL-4–, IFN-–,
and IL-10–secreting T cells (one allergic and one
healthy donor each; closed symbols, allergic donors;
open symbols, healthy donors) were in vitro expanded
for 2 wk, and their cytokine profile was determined in
supernatants by ELISA 72 h after anti-CD2, anti-CD3,
and anti-CD28 mAb stimulation. (C) Intracytoplasmic
cytokine profile of in vitro–expanded allergen-specific
T cells (the same results were obtained in 10 additional
experiments). Percentage of positive cells is shown in
each quadrant.
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PRISM 7000; Applied Biosystems). Relative quantification was
performed as described previously (28). All amplifications were
performed in duplicates.
Statistical Interpretation. Data are expressed as mean  SEM.
Student’s t test, Z test, and Mann-Whitney U test were used for
statistical analysis.
Online Supplemental Material. Fig. S1 contains sample data of
the purification and frequency calculation of allergen-specific
CD4 cells according to their cytokine profile. Details of flow
cytometric analysis are shown, from allergen stimulation to fre-
quency calculation of purified IL-10–secreting Tr1 cells. Online
supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20032058/DC1.
Results
Allergen-specific IL-4–, IFN-–, and IL-10–secreting T Cells
Represent Th2-, Th1-, and Tr1-like Cells. To investigate
the regulation of specific immune response against environ-
mental protein antigens, we isolated CD4 T cells specific
to several food and aeroallergens from healthy and allergic
individuals according to their IL-4, IFN-, and IL-10 secre-
tion profile (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20032058/DC1). To confirm their cyto-
kine profile, mRNA of IL-10, IL-13, IFN-, and TGF-
were quantified immediately after isolation (Fig. 1 A). Re-
lative to the housekeeping gene EF-1, IL-10–secret-
ing T cells expressed significantly high IL-10 mRNA and
IFN-–secreting T cells expressed significantly high IFN-
mRNA. IL-13 mRNA was dominant in IL-4–secreting T
cells. Quantification of cytokines after in vitro expansion of
IL-4–, IL-10–, and IFN-–secreting T cells revealed that
these subsets contain Th2-like (IL-4, IL-5, and IL-13 high),
Th1-like (IFN- high), and Tr1-like (IL-10 and TGF-
high) cells, respectively (all P  0.0001 compared with
other subsets; Fig. 1, B and C). In addition, all three puri-
fied subsets consisted of some Th0 cells, which secrete both
Th1 and Th2 cytokines as well as IL-10 and TGF-. There
was no difference in cytokine profile at the single T cell
subset level between allergic and healthy individuals.
The antigen specificity of purified cytokine-secreting T
cells was studied by stimulation with the allergen that was
originally used for stimulation before purification and sev-
eral control antigens in the presence of autologous APCs.
Consistently, IL-10–secreting T cells showed very little or
no allergen-induced proliferation (Fig. 2 A). The prolifera-
tive response of allergen-specific IL-4– and IFN-–secret-
ing T cells was significantly high compared with IL-10–
Figure 2. Specificity and growth requirements of purified allergen-
specific T cells. (A) Bet v 1–, Der p 1–, and Cor a 1–specific IL-4–,
IFN-–, and IL-10–secreting T cells (one allergic and one healthy
donor each; closed symbols, allergic donors; open symbols,
healthy donors) were purified and in vitro expanded, and 5  105
cells were cocultured with 5  105 autologous irradiated PBMCs
as an APC source in the presence of the same antigen. [3H]Thymi-
dine incorporation (TdR) was determined after 5 d. *, P  0.001.
(B) Purified Bet v 1–specific and Der p 1–specific T cells did not
show any proliferative response to different control antigens (two
representative of six experiments are shown; mean  SD of triplicate
cultures). TT, tetanus toxoid; us, unstimulated. (C) Growth factor
requirements of antigen-specific IL-10–secreting T cells. After purifi-
cation, Bet v 1– or Der p 1–specific IL-10–secreting T cells were
first expanded for 10 d in the presence of IL-2, washed, and cultured
(5  104 cells) with 1-nM doses of different cytokines. [3H]Thy-
midine incorporation was determined after 3 d (mean  SD of
three independent experiments are shown).
Figure 3. Increased frequency of allergen-specific Tr1 cells in healthy
individuals and Th2 cells in allergic individuals. (A) Frequency of Der p 1–
and Bet v 1–specific, cytokine-secreting CD4 T cells from eight allergic
individuals and Cor a 1–, Bet v 1-, Der p 1–, and Pyr c 5–specific, cytokine-
secreting CD4 T cells from 15 healthy individuals out of pollen season.
(B) Frequency of Der p 1–specific T cells in six allergic and six healthy,
and Bet v 1–specific T cells in three allergic and three healthy individuals
by ELISPOT assay. *, P  0.01; **, P  0.001.
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secreting T cells. There was no difference between different
allergens. T cells purified by certain antigen stimulation did
not show any cross-reactivity against control antigens (Fig. 2
B). All three subsets purified by Bet v 1 stimulation re-
sponded to Bet v 1, but not to tetanus toxoid and Der p 1.
Similarly, Der p 1–specific T cell subsets showed prolifera-
tive response to Der p 1, but not to tetanus toxoid and Bet v
1 as control antigens. Although they did not proliferate by
antigen stimulation, IL-10–secreting T cells used IL-2, IL-4,
IL-7, and IL-15 as growth factors and showed significant
proliferation (Fig. 2 C). Together with the quantitative cy-
tokine mRNA profiles of freshly purified cells, these data
demonstrate that allergen-specific Tr1-, Th1-, and Th2-like
cells can be purified from human peripheral blood.
Balance between Allergen-specific Tr1 Cells and Th2 Cells
Characterizes Healthy and Allergic Immune Response. As it
was possible to purify single allergen-specific Th1-, Th2-,
and Tr1-like cells, their frequency and functional proper-
ties were investigated in the next step. The frequency of T
cell subsets specific to different mucosal allergens was com-
pared in healthy and allergic individuals using two different
techniques. Recombinant major allergens of house dust
mite (Der p 1) and birch pollen (Bet v 1) were used as
aeroallergens, and pear (Pyr c 5) and hazelnut (Cor a 1)
were used as food antigens to analyze the frequency of spe-
cific Th1-, Th2-, and Tr1-like cells. Although specific T
cells that belong to all three subsets were detectable in both
healthy and allergic individuals, allergen-specific IL-10–
secreting T cells were the predominant subset in healthy
individuals. We found similar results for each allergen. In
contrast, an increased frequency of IL-4–secreting T cells
was observed in allergic patients (Fig. 3 A). ELISPOT was
used as an alternative method in allergen-stimulated PBMC
cultures and demonstrated a similar frequency distribution
of Der p 1– and Bet v 1–specific T cell subsets (Fig. 3 B).
As aforementioned, all three subsets of single allergen-spe-
cific T cells are present in both healthy and allergic individu-
als. Accordingly, their role on allergen-induced T cell prolif-
eration and whether this is influenced by changing their
ratios was investigated. We assayed the allergen-induced
proliferation of IL-4– and IL-10–secreting T cells by adding
those purified cells back into autologous PBMCs. First, the
antigen-specific suppressor effect of IL-10–secreting T cells
was analyzed (Fig. 4 A). Bet v 1– and Der p 1–specific IL-4–
and IL-10–secreting T cells were separately purified from the
same healthy individuals. Their frequency was increased up
to 10 times higher than initial levels in PBMCs. PBMCs
alone did not show allergen-induced T cell proliferation,
which was achieved by increasing the numbers of allergen-
specific IL-4–secreting T cells. Der p 1–specific IL-10–
Figure 4. Antigen-specific suppression by Tr1 cells. (A) Der p
1–specific and Bet v 1–specific IL-4–secreting and IL-10–secreting
T cells were purified from healthy individuals. Their frequency was
calculated in CD4 T cells, and 2  105 PBMCs were immediately
reconstituted by increasing their frequency by 10 times (IL-4–
secreting T cells, 0.02–0.2%; IL-10–secreting T cells, 0.05–0.5%).
Cells were stimulated with the respective antigens and PPD. (B) Der
p 1–specific IL-4–secreting and IL-10–secreting T cells were purified
and in vitro expanded by IL-2/IL-4 and IL-2/IL-15, respectively.
2  105 PBMCs were enriched with 1,000 Der p 1–specific IL-4–
or IL-10–secreting T cells or their combinations in IL-4–secreting/
IL-10–secreting T cell ratios 1,000/1,000 (1:1), 1,000/500 (2:1),
1,000:250 (4:1), and 1,000:125 (8:1). Cells were stimulated with
0.3 	M Der p 1 or 1 	g/ml PPD. Der p 1–specific, IL-10–secreting
T cells added to PPD-stimulated PBMC cultures at indicated
numbers did not show any suppression. (C) The same experimental
design as in A was used, and cells were stimulated with both Der p 1
and Bet v 1 (0.3 	M each). (A–C) [3H]Thymidine incorporation was
determined after 5 d. The same results were obtained in three
other experiments. *, P  0.001. (D) 105 PBMCs were stimulated
with anti-CD3 in the presence of different amounts of IL-10–
secreting and IL-4-secreting T cells. [3H]Thymidine incorporation
was determined after 3 d. Data represent two different experi-
ments. *, P  0.01.
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secreting T cells only suppressed Der p 1–stimulated, but not
Bet v 1– or PPD-stimulated proliferation. Similarly, Bet v
1–specific IL-10–secreting T cells only suppressed Bet v
1–stimulated, but not Der p 1– or PPD-stimulated prolifera-
tion. There was no cross-suppression of Der p 1–specific IL-
10–secreting cells on Bet v 1 stimulation and Bet v 1–specific
IL-10–secreting T cells on Der p 1 stimulation, as well as
both IL-10–secreting T cells on PPD stimulation.
The retention of suppressive activity of Tr1 cells after
expansion ex vivo is obviously an absolute prerequisite for
usage in a possible cellular therapeutic approach. We tested
whether in vitro–expanded IL-10–secreting T cells main-
tain their suppressive activity. PBMCs of healthy individu-
als showed no or very limited proliferative response to Der
p 1. The addition of in vitro–expanded Der p 1–specific
IL-4, but not IL-10–secreting T cells significantly enhanced
Der p 1–induced proliferation (Fig. 4 B). Increased num-
bers of in vitro–expanded IL-10–secreting T cells signifi-
cantly suppressed IL-4–secreting T cell–mediated prolifera-
tion in Der p 1–stimulated PBMCs. A 1:1 ratio of effector
(IL-4–secreting) to suppressor (IL-10–secreting) T cells was
required for full suppression of T cell proliferation. In con-
trast, PPD-stimulated proliferation was not suppressed by
Der p 1–specific IL-10–secreting T cells.
To test whether the IL-10–secreting T cells induce by-
stander suppression on other T cells in their vicinity, we
cultured Der p 1–specific, IL-4–secreting cells with freshly
purified Der p 1– or Bet v 1–specific IL-10–secreting cells
in the presence of both Der p 1 and Bet v 1 (Fig. 4 C). Der
p 1–specific, IL-4–secreting T cell proliferation was sup-
pressed by Der p 1–, but not Bet v 1–specific Tr1 cells. As
few as 1,000 Tr1 cells were able to induce antigen-specific
suppression in 200,000 PBMCs. High numbers of freshly
purified Tr1 cells (at least 20,000 in 100,000 PBMCs) re-
sulted in a nonspecific suppressive activity on anti-CD3–
stimulated T cells (Fig. 4 D). In comparison, IL-4–secreting
T cells did not exert any suppressive effect on anti-CD3
stimulation. These data demonstrate allergen-specific sup-
pressor activity of Tr1 cells and the importance of the bal-
ance between allergen-specific Th2 and Tr1 cells for aller-
gen-induced T cell activation.
Allergen-specific Tr1 Cells Use Multiple Suppressor Factors.
Molecules that may play a role on suppressive mechanisms
of allergen-specific IL-10–secreting T cells were analyzed
Figure 5. Expression of suppressor molecules on IL-10–secreting T
cells. (A) Immediately after purification, antigen-specific IL-10–secreting
T cells of healthy individuals were analyzed for intracytoplasmic IL-10,
surface IL-10R, CTLA-4, CD25, and PD-1 by flow cytometry. Data are
compared with CD3 T cells of the same donor stimulated with the same
antigen. (B) TGF- RI and RII expression by immunohistology. (A and
B) Same results were obtained in three independent experiments.
Figure 6. Multiple suppressive mechanisms play a role in peripheral
allergen tolerance. (A) Endogenous IL-10, TGF-, or both as well as
CTLA-4, PD-1, or both were neutralized in Der p 1–stimulated PBMCs
of healthy individuals. [3H]Thymidine incorporation (TdR), IFN-, and
IL-13 were determined at day 5. (B) Der p 1–specific proliferation of
PBMCs from house dust mite allergic patients was suppressed by 10 times
increased frequency of Der p 1–specific, IL-10–secreting T cells (IL-10).
The activity of IL-10, TGF-, CTLA-4, and PD-1 were neutralized.
[3H]Thymidine incorporation (TdR), IFN-, and IL-13 were deter-
mined at day 5. (control) Isotype control antibody. (A and B) Same results
were obtained in four independent experiments (two Bet v1 and two Der
p 1) all performed with freshly purified cells without in vitro expansion.
Bet v 1 stimulation in birch pollen–allergic individuals gave similar results.
All of the neutralization experiments were significantly different from the
control and IL-10–secreting T cell–suppressed condition at 0.3 	M aller-
gen doses. P  0.001.
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on freshly purified cells (Fig. 5). IL-10–secreting T cells
expressed high amounts of IL-10, IL-10R chain, TGF-
receptors I and II, CTLA-4, CD25, and PD-1, suggesting
that multiple suppressor factors may play a role on sup-
pression of allergen-specific Th2 cells by Tr1 cells in
healthy individuals.
Neutralization experiments revealed that all four sup-
pressive mechanisms may play a role in suppression of aller-
gen-specific Th2 cells. Der p 1– or Bet v 1–stimulated
PBMCs of healthy individuals did not show any T cell pro-
liferation. In both cases, neutralization of IL-10 and TGF-
activity significantly enhanced antigen-induced prolif-
eration as well as IL-13 and IFN- production (Fig. 6 A).
In addition, two other mechanisms apparently function
in healthy immune response to allergens because neutral-
ization of CTLA-4 or PD-1 significantly enhanced T cell
proliferation and IFN- and IL-13 secretion in healthy in-
dividuals. In allergic individuals, Der p 1–induced T cell
proliferation was significantly high in PBMCs of house dust
mite allergic donors. A very clear suppression was achieved
by increasing the frequency of Der p 1–specific, IL-10–
secreting T cells. This suppression was partially inhibited by
blocking of IL-10R, TGF-, CTLA-4, or PD-1 (Fig. 6 B).
In these experiments, IL-10R–blocking mAbs may block
IL-10R on the APCs as well as on Tr1 cells; in addition,
TGF- secreted from both Tr1 cells and APCs can be neu-
tralized by sTGF-R. CTLA-4 and PD-1 are blocked par-
ticularly on the surface of Tr1 cells. These data demonstrate
that IL-10, TGF-, CTLA-4, and PD-1 cooperate in the
suppression of immune response to allergens.
Discussion
The present work demonstrates that immune response to
allergens in health and disease is the result of a balance be-
tween allergen-specific Tr1 cells and allergen-specific Th2
cells. Active regulation has emerged as a very essential
mechanism for both inducing and equally importantly
maintaining specific immunological nonresponsiveness. By
analyzing Tr1 cells specific to various food or inhalant anti-
gens, we demonstrated that similar mechanisms take place in
healthy immune response to mucosal allergens. The IL-10–
secreting allergen-specific T cells represented the predomi-
nant subset with significantly high frequency in comparison
to IL-4– and IFN-–secreting T cells in healthy individuals.
Both ELISPOT for cytokines and purification of cytokine-
secreting T cells gave similar frequency numbers. Mecha-
nisms that control the in vivo shift between allergen-specific
T cell subsets remain to be elucidated. It can be hypothe-
sized that a switch in cytokine profile and apoptosis of effec-
tor T cells may play a role in the generation of an atopic
phenotype (29, 30). The stability of cytokine profile in dif-
ferentiated effector and memory T cell subsets in humans is
not fully known, and recent studies have demonstrated that
lineage-committed memory T cell subsets are responsive to
cytokine signals of the opposing lineage (30, 31). In addi-
tion, Tr1 cells do not appear to be anergic and may effi-
ciently expand in vivo (32) as they are shown to proliferate
by IL-2, IL-4, IL-7, and IL-15 in the present work.
There is clear evidence from various animal models and
human studies for an active mechanism of immune sup-
pression, whereby a distinct subset of T cells inhibits the
activation of conventional T cells in the periphery (7, 13,
14, 33). This Tr cell population has been determined as
CD4CD25 T cells. They can prevent the development
of autoimmunity, indicating that the normal immune sys-
tem contains a population of professional regulatory T cells.
Elimination of CD4CD25 T cells leads to spontaneous
development of various autoimmune diseases, such as gas-
tritis or thyroiditis, in genetically susceptible hosts. The fre-
quency of CD4CD25 Tr cells is 10–15% of CD4 T
cells, whereas the frequency of IL-10–secreting T cells of a
single allergen specificity ranges between 0.1 and 0.007% of
CD4 T cells. This shows that the frequency of single al-
lergen-specific Tr1 cells, which are also CD4 CD25,
ranges between 1 in 1,000 and 1 in 20,000 of the whole
CD4 CD25 Tr cell population.
Although many aspects of the mechanisms by which
suppressor cells exert their effects remain to be elucidated,
it is well established that Tr cells suppress immune re-
sponses via cell-to-cell interactions and/or the production
of IL-10 and TGF- (10, 11, 34, 35). Tr1 cells specific for
a variety of antigens arise in vivo, but may also differentiate
from naive CD4 T cells in the presence of IL-10 in vitro
(36). The nonspecific T cell suppressor activity of IL-10
and TGF- has been consistently reported in experiments
with high amounts of exogenously added suppressor cyto-
kines (21, 25). However, the present work demonstrates
that Tr1 cells display antigen-specific suppressor activity in
very low numbers. If the number of cells exceed a thresh-
old that provides sufficient quantities of suppressor signals,
apparently they show nonspecific suppression. Depending
on their frequency, the first T cell that contacts the APC
may be very critical in the subsequent decision to stimulate
or suppress the specific immune response. If the first T cell
to contact the APC is a Tr1 cell, it may silence or regulate
the maturation of APC. IL-10 down-regulates the antigen-
presenting capacity, such as HLA-DR expression, costimu-
latory molecules, and several cytokines in dendritic cells
and monocytes/macrophages (37). Recently, differentia-
tion of a distinct dendritic cell subset in the presence of IL-
10 has been demonstrated that induces tolerance through
the generation of Tr1 cells (38). In addition, exposure of
mature pulmonary dendritic cells to respiratory allergens
stimulated the development of Tr1-like cells, which was
dependent on dendritic cell IL-10 production (39). To-
gether, these findings suggest that IL-10–secreting T cells
may regulate the functional state of APCs in a way that
these APCs can now promote the generation of Tr1 cells.
CD4CD25 T cells are the only lymphocyte subpopu-
lation in mice and humans that express CTLA-4 constitu-
tively. The expression apparently correlates with the sup-
pressor function of CTLA-4. As demonstrated in the
present work, the blocking of CTLA-4 activity of Tr1 cells
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reverses suppression in cocultures of CD4CD25 and
CD4CD25 T cells (40). Similarly, the treatment of mice
that were recipients of CD4CD45RBlow T cells with
CTLA-4–blocking agents, abrogated the suppression of in-
flammatory bowel disease (41). These studies indicate that
signals that result from the engagement of CTLA-4 by its
ligands, CD80 or CD86, are required for the induction of
suppressor activity. Under some circumstances, the en-
gagement of CTLA-4 on the CD4CD25 T cells by an-
tibody or by CD80/CD86 might lead to inhibition of the
TCR-derived signals that are required for the induction of
suppressor activity.
A subset of human Tr1 cells expressed functional PD-1
in the present work. PD-1 is an immunoreceptor tyrosine-
based inhibitory motif–containing receptor expressed upon
T cell activation. PD-1–deleted mice develop autoimmune
diseases, suggesting an inhibitory role for PD-1 in immune
responses (42). Members of the B7 family, PD-ligand (L)1
and PD-L2, are ligands for PD-1. PD-1/PD-L engagement
on murine CD4 and CD8 T cells results in inhibition of
proliferation and cytokine production. T cells stimulated
with anti-CD3/PD-L1Fc-coated beads display dramatically
decreased proliferation and IL-2 production (43).
Collectively, our results indicate that the control of Th2
immune response against naturally exposed harmless envi-
ronmental antigens is mediated by Tr1 cells in humans. Ef-
fector (allergen-specific Th2) and suppressor (allergen-
specific Tr1) T cells exist in both healthy and allergic indi-
viduals in certain amounts. Their ratio determines the de-
velopment of a healthy or an allergic immune response.
These data may explain the spontaneous development and
spontaneous healing of allergic diseases. Although in low
frequency, the existence of potential suppressive allergen-
specific Tr1 cells in allergic individuals suggests a possible
way of treatment. The knowledge of this cellular and mo-
lecular basis is pivotal in understanding the mechanisms of
immune tolerance or allergy development against harmless
environmental proteins.
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6.3 A second step of chemotaxis after transendothelial 
migration: keratinocytes undergoing apoptosis release IFN-!-
inducible protein 10, monokine induced by IFN-! , and IFN-!-
inducible "-chemoattractant for T cell chemotaxis toward 
epidermis in atopic dermatitis. 
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A Second Step of Chemotaxis After Transendothelial
Migration: Keratinocytes Undergoing Apoptosis Release
IFN--Inducible Protein 10, Monokine Induced by IFN-, and
IFN--Inducible -Chemoattractant for T Cell Chemotaxis
Toward Epidermis in Atopic Dermatitis1
Sven Klunker,* Axel Trautmann,* Mu¨beccel Akdis,* Johan Verhagen,*
Peter Schmid-Grendelmeier,*† Kurt Blaser,* and Cezmi A. Akdis2*
Activation and skin-selective homing of T cells and their effector functions in the skin represent sequential immunological events in the
pathogenesis of atopic dermatitis (AD). Apoptosis of keratinocytes, induced mainly by T cells and mediated by IFN- and Fas, is the
essential pathogenetic event in eczema formation. Keratinocyte apoptosis appears as activation-induced cell death in AD. By IFN-
stimulation, chemokines such as IFN--inducible protein 10, monokine induced by IFN-, and IFN--inducible -chemoattractant are
strongly up-regulated in keratinocytes. These chemokines attract T cells bearing the specific receptor CXCR3, which is highly expressed
on T cells isolated from skin biopsies of AD patients. Accordingly, an increased T cell chemotaxis was observed toward IFN--treated
keratinocytes. Supporting these findings, enhanced IFN--inducible protein 10, monokine induced by IFN-, and IFN--inducible
-chemoattractant expression was observed in lesional AD skin by immunohistochemical staining. These results indicate a second step
of chemotaxis inside the skin after transendothelial migration of the inflammatory cells. Keratinocytes undergoing apoptosis in acute
eczematous lesions release chemokines that attract more T cells toward the epidermis, which may further augment the inflammation and
keratinocyte apoptosis. The Journal of Immunology, 2003, 171: 1078–1084.
C hemokines are a superfamily of small structurally relatedproteins that regulate the traffic of lymphocytes, dendriticcells, monocytes, neutrophils, and eosinophils. They are
classified into C, CC, CXC, and CX3C subfamilies, based on the
position of characteristic structure determining cysteine residues
within the N-terminal part of the proteins (1–3). Another classifi-
cation distinguishes chemokines in inflammatory (inducible) and
homeostatic (constitutive, housekeeping or lymphoid) chemokines
(4–9). Homeostatic chemokines are constitutively produced in dis-
crete microenvironments within lymphoid or nonlymphoid tissues
including skin and mucosa. They are responsible for maintaining
physiological traffic and positioning of cells that mainly belong to
the adaptive immune system. Inflammatory chemokines are ex-
pressed after stimulation by proinflammatory cytokines or after
contact with pathogenic agents. This causes the recruitment of ef-
fector cells, such as monocytes, granulocytes, and effector T cells
(4). IFN--inducible protein 10 (IP-10,3 CXCL10), monokine in-
duced by IFN- (Mig, CXCL9), and IFN--inducible -chemoat-
tractant (iTac, CXCL11) belong to the group of inflammatory che-
mokines. They are all induced by IFN-, which inhibits the
expression of most other chemokines (10, 11), and these three
chemokines share a common receptor, CXCR3 (12).
Atopic dermatitis (AD) is a chronic inflammatory skin disease
that frequently predates the development of allergic rhinitis or
asthma (13, 14). Elevated IgE levels and eosinophilia in AD sug-
gest increased expression of Th2-type cytokines. The majority of
allergen-specific T cells derived from skin lesions that have been
provoked in AD patients by epicutaneous allergen application or
peripheral blood skin- homing T cells produce predominantly Th2
cytokines such as IL-4, IL-5, and IL-13 (15–18). Previously, such
a polarized Th2 cytokine pattern was regarded as a specific feature
reflecting immune dysregulation in AD. However, recent studies
have demonstrated that IFN- predominates over IL-4 in chronic
skin lesions and older patch test reactions in AD, whereas IL-5 and
IL-13 still remain at high levels (19–22).
Lesional AD skin is characterized with dermal mononuclear cell
infiltrate and spongiosis in the epidermis. Apoptosis of keratino-
cytes induced by T cells and mediated by IFN- and Fas (CD95)
is a crucial event in the transition from activation of the immune
system to the manifestation of eczematous dermatitis (23). Appar-
ently, keratinocyte apoptosis is an activation-induced cell death,
because IFN- up-regulates Fas, ICAM-1, and HLA-DR and ren-
ders keratinocytes susceptible to apoptosis (24). Induction of ker-
atinocyte apoptosis by skin-infiltrating T cells, subsequent cleav-
age of E-cadherin, and resisting desmosomal cadherins represent
molecular events in spongiosis formation (25).
We investigated whether T cell-keratinocyte interaction contrib-
utes to the intensity of skin inflammation and tissue injury mech-
anisms. Here, we demonstrate that keratinocytes undergoing T
cell- and particularly IFN--mediated activation-induced cell
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death release chemokines such as IP-10, Mig, and iTac. These
chemokines play a role in a second step of chemotaxis from the
dermis to the epidermis that increases the severity of tissue injury
and keratinocyte apoptosis in the AD skin.
Materials and Methods
Subjects
Nineteen patients with AD (19–68 years of age) were diagnosed according
to standard criteria of Hanifin and Rajka (26). They were all allergic to at
least three environmental allergens, and serum IgE was 500 U/ml. Ten
healthy subjects (22–42 years of age) had no allergic disease and had
normal levels of serum IgE. The study was approved by the Ethical Com-
mittee of Davos.
Abs and reagents
All fluorescent- or biotin-labeled mAbs for flow cytometry analysis were
purchased from Immunotech (Marseilles, France) or BD PharMingen (San
Diego, CA). Anti-CD45RO, anti-CD45RA magnetic microbeads for
MACS were from Miltenyi Biotec (Bergisch Gladbach, Germany). Human
IFN-, IL-2, and IL-4 were provided by Novartis (Basel, Switzerland).
Ethidium bromide was from Sigma-Aldrich (St. Louis, MO). Soluble Fas
ligand and TNF- were from Alexis Biochemicals (San Diego, CA). Abs
to human IP-10, Mig, and iTac for immunohistochemistry were purchased
from PeproTech EC (London, U.K.).
Keratinocyte culture
Primary human keratinocytes (pooled normal human epidermal keratino-
cytes from neonatal skin) were purchased from BioWhittaker (Walkers-
ville, MD) and grown in keratinocyte growth medium (KGM-2) from the
same company supplemented with bovine insulin, hydrocortisone, human
recombinant epidermal growth factor, 30 g/ml bovine pituitary extract,
100 g/ml gentamicin, 1000 ng/ml amphotericin B, epinephrine, trans-
ferrin, and calcium. Hydrocortisone was not added in experiments.
Human HaCaT keratinocytes, a gift from N. E. Fusenig (German Cancer
Research Center, Heidelberg, Germany), (27), were grown in RPMI 1640
supplemented with 1 mM L-glutamine, sodium pyruvate, nonessential
amino acids, and 10% FCS (all from Life Technologies, Basel,
Switzerland).
Real time RT-PCR mRNA expression analysis
Total RNA from keratinocytes was extracted using the RNeasy kit (Qiagen,
Basel, Switzerland) according to the manufacturer’s instructions. During
this procedure, a DNase digestion with the RNase-free DNase set for use
with RNeasy/QIAamp columns (Qiagen) was used. RNA was reverse tran-
scribed using Omniscript reverse transcriptase (Qiagen). The resulting
cDNA was analyzed by real time PCR (Light Cycler; Roche Diagnostics,
Mannheim, Germany). The probes for IP-10 were: Red640LC-labeled
(LC), 5-LC Red640-act gga ggt tcc tct gct gta ggc tc p; and fluorescein-
labeled (FL), 5-aat cgc agt ttg att cat ggt gct ga x. The primers for IP-10
were: forward, 5-gac att cct caa ttg ctt aga cat a; and reverse, 5-aat gat ctc
aac acg tgg aca a. The probes for Mig were: LC, 5-LC Red640-cct aca caa
ttc act gaa cct ccc ctg p; and FL, 5-ggt tta aat tct ggc cac aga caa cct c x.
The primers for Mig were: reverse, 5-tag ata aga cgt tcg ggt ggg at and
forward, 5-cgg tta gtg gaa gca tga ttg g. The probes for iTac were: LC,
5-LC Red640-gac agc gtc ctc ttt tga aca tgg g p; and FL, 5-ctg ctt tta ccc
cag ggc cta tgc x. The primers for iTac were: forward, 5-tgg ctg tga tat tgt
gtg cta ca; and reverse, 5-ctt cga ttt ggg att tag gca. All primers and probes
were designed and obtained from TIB MOLBIOL (Berlin, Germany). For
amplification of the PCR product, the Light Cycler-Fast Start DNA Master
Hybridization Probes (Roche Diagnostics) were used according to the man-
ufacturer’s instructions. The forward primer sequence for GAPDH was
5-gct gat gat ctt gag gct gtt g-3, and the reverse primer sequence was
5-ctt cgc tct ctg ctc ctc ct-3. The GAPDH was amplified in the real time
PCR using the Light Cycler-Fast Start DNA Master SYBR Green I (Roche
Diagnostics).
Quantification of the amplicons in each well was determined according
to the comparative threshold cycle number (Ct) method as previously de-
scribed (Applied Biosystems, Foster City, CA). Briefly, the formula for
each sample is 2E  (Cttarget  Ctstandard). This yields a quantification of
the target PCR products relative to the PCR products for the internal cal-
ibration (GAPDH) and unstimulated control keratinocytes. The results
were plotted on a log scale.
RNase protection assay mRNA expression analysis
Total RNA was extracted using a guanidine isothiocyanate-acid phenol
protocol. For simultaneous RNase protection assay of RANTES (CCL5),
IP-10, monocyte chemoattractant protein (MCP-1, CCL2), and IL-8, the
multiprobe template set hCK5 was used; hCR-6 was used for the detection
of CXCR1, CXCR2, CXCR3, and CXCR4 (BD PharMingen) according to
the manufacturer’s instructions. The unprotected RNA was digested using
a RNase T1/A mix. The digested RNA was purified and loaded on a 6%
urea gel. The dried radioactive gels were exposed to imager plates and
visualized by an imager system (FLA-3000; Raytest, Urdorf, Switzerland).
RNase protection assay bands were quantified by using the AIDA software
(Raytest).
T cell cultures
PBMC were isolated by Ficoll (Biochrom, Berlin, Germany) density gra-
dient centrifugation of peripheral venous blood of normal donor and cord
blood (28). Cells were washed three times and resuspended in DMEM
(Life Technologies, Switzerland), supplemented as described (16).
CD45RO and CD45RA cells were negatively selected with the MACS
magnet activated cell separation system (Miltenyi Biotech) (16, 17). In
brief, anti-CD14 and anti-CD19 depleted cells were incubated with MACS
microbead-conjugated anti-CD45RO and anti-CD16 mAbs and anti-CD8.
For the differentiation of Th1 and Th2 cells, freshly isolated cord blood
CD4CD45RA T cells were suspended in RPMI 1640 medium supple-
mented as described (16). The cells were cultured in 48-well plates at a cell
density of 105/ml. They were stimulated with the combination of mAbs to
T cell surface molecules anti-CD2 (two mAbs, 4B2 and 6G4 each 0.5
g/ml), anti-CD3 (1 g/ml), and anti-CD28 (1 g/ml), and IL-2 (20 ng/
ml). For Th1 differentiation, human IL-12 (10 ng/ml) and neutralizing anti-
IL-4 mAb (10 g/ml) were added to individual wells (29). For Th2 dif-
ferentiation, human IL-4 (25 ng/ml) and neutralizing anti-IL-12 (10 g/ml)
were used (29). The growing cell cultures were expanded with fresh culture
medium containing human IL-2. After 12 days, the cells were harvested,
washed, and then restimulated with mAbs to CD2/CD3/CD28, and cyto-
kine patterns of differentiated cells were determined by flow cytometry and
ELISA.
To isolate T cells from epidermis of lesional biopsies of AD patients,
epidermis pieces (0.5–1 mm) of the skin biopsy specimens from 3- to
4-day-old lesions of four chronic AD patients were minced with two scal-
pels (no proteolytic enzymes were used). Pieces of epidermis were stim-
ulated in complete RPMI 1640 with 25 U/ml IL-2 and anti-CD2, anti-CD3,
and anti-CD28 mAb. Growing T cells were expanded in medium contain-
ing IL-2 (purity was 100% as assessed by flow cytometry). After 7–10
days, the cytokine profile and chemokine receptors were characterized
(19). The supernatants were collected 48 h after anti-CD2, anti-CD3, and
anti-CD28 mAb stimulation; frozen; and used for the chemokine expres-
sion experiments or ELISA measurements of cytokines.
Quantification of cytokines by ELISA
The cytokine profiles of the T cells that were isolated from skin biopsies
were evaluated in a sandwich ELISA (16, 28) by measuring IL-4, IL-5,
IL-13, and IFN-. The sensitivity of IFN- ELISA was 10 pg/ml (mAb
and IFN- standard were gifts from Dr. S. S. Alkan, Novartis). The sen-
sitivity of IL-4 ELISA was 20 pg/ml (mAb and IL-4 standard were pro-
vided by Dr. C. H. Heusser, Novartis). The detection limit of the IL-5
ELISA was 50 pg/ml (mAb and IL-5 standard were from BD PharMingen).
The sensitivity of the IL-13 ELISA was 100 pg/ml (mAb and IL-13 stan-
dard were from BD PharMingen).
Chemotaxis assay
CD45RO T cells (1  106)/ml were stimulated with a combination of
soluble anti-CD2, anti-CD3, and anti-CD28 mAb. The cells were stained
with Cell Tracker Green CMFDA (Molecular Probes, Eugene, OR; 5 M
in medium) for 45 min under growth conditions.
Keratinocytes were grown in a 24-well plate until a confluence of80%
was reached. A fluoro-block insert (BD Biosciences, Basel, Switzerland)
with a pore size of 3 m was used to separate the fluorescence-labeled T
cells from the keratinocytes at the bottom of the well. Keratinocytes were
pretreated for 12 h with 10 ng/ml IFN- or 10 ng/ml TNF-. Migration
occurred through the pores of the membrane and was measured by the
amount of fluorescence in the lower part of the well with an imager system,
FLA-3000 (Raytest).
Immunohistochemistry
Biopsy specimens were taken from 3- to 4-day-old lesions of chronic AD
patients or from normal skin of healthy individuals. Frozen 4-m skin
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sections were fixed with 4% paraformaldehyde for 20 min. Endogenous
peroxidases were quenched with a 0.3% H2O2 solution in methanol. Non-
specific binding was blocked with 10% normal goat serum (Chemicon,
Temecula, CA) and then incubated for 2 h with the appropriate dilution of
Abs, anti-human CD4 (BD PharMingen), anti-human IP-10, anti-human
iTac, or anti-human Mig (all from PeproTech EC) or rabbit IgG as isotype
control. Sections were then treated with biotin-labeled goat anti-rabbit IgG
and stained with avidin-biotin-peroxidase (Vector, Burlingame, CA), fol-
lowed by 3,3-diaminobenzidine (Sigma-Aldrich) development.
Flow cytometry
Keratinocytes or T cells were incubated with appropriate FITC- or PE-
labeled mAb for 30 min at 4°C and then fixed in 2% paraformaldehyde (pH
7.4). Negative control cells were prepared in a similar fashion with isotype
control IgG1-FITC/PE mAb. Fluorescence intensity was measured by flow
cytometry (EPICSTMXL-MCL; Beckmann Coulter, Nyon, Switzerland).
KC viability was monitored by ethidium bromide (1 M; Sigma-Aldrich)
uptake and flow cytometry as previously described (30).
Statistical analysis
Student’s t test was used for statistical analysis. Data are presented as the
mean  SD of triplicate cultures.
Results
IFN--, TNF--, and T cell-mediated death of human
keratinocytes
Primary human keratinocytes or HaCaT keratinocytes were cul-
tured with IFN-, TNF-, soluble Fas (sFas) ligand, and anti-CD2/
CD3/CD28 mAb stimulated supernatant of T cells isolated from
AD skin, and cell viability was measured (Fig. 1). A significantly
increased keratinocyte death was induced after 5 days by super-
natants of stimulated T cells isolated from AD skin and conditions,
which contain IFN- ( p 0.001). TNF- induced a relatively low
level and late keratinocyte death. Triggering of Fas alone on ker-
atinocytes did not induce keratinocyte death. In our previous stud-
ies, IFN- and sFas-ligand were identified as keratinocyte apop-
tosis-inducing factors within the activated T cell supernatants. The
type of T cell-induced keratinocyte death was also shown to be
apoptosis by using several different apoptosis-specific methods
(23, 25).
IFN- induces IP-10, Mig, and iTac in human keratinocytes
Because T cells are essential players in keratinocyte apoptosis,
factors that attract T cells toward and into the epidermis of lesional
AD skin are further investigated. Because IFN- and TNF- are
two major proinflammatory cytokines in eczematous skin, we inves-
tigated whether they affect release of chemokines by keratinocytes. In
FIGURE 1. Role of T cells and cytokines on keratinocyte death. Pri-
mary human keratinocytes were incubated with 10 ng/ml IFN-, 10 ng/ml
TNF-, 10 ng/ml sFas ligand (sFasL), and 50% (v/v) T cell supernatant
(sup., 48-h anti-CD2/CD3/CD28 mAb-activated AD skin T cell superna-
tant) and left unstimulated (u.s.). KC viability was monitored by ethidium
bromide exclusion and flow cytometry. One representative of five experi-
ments with primary human keratinocytes is shown. Same results were ob-
tained with HaCaT keratinocytes. Standard deviation of triplicate cultures
is shown. , p  0.001; , p  0.05.
FIGURE 2. IFN- induces IP-10,
Mig, and iTac in human keratino-
cytes. A, RNase protection assay of
cultured primary keratinocytes shows
constitutive expression of IL-8
mRNA and induction of IP-10
mRNA after treatment with 10 ng/ml
IFN- or IFN- and an additional 10
ng/ml TNF-. B, Real time RT-PCR
shows up-regulation of IP-10, iTac,
and Mig mRNA after treatment of
primary keratinocytes with 50% (v/v)
T cell supernatant (sup.; 48 h anti-
CD2/CD3/CD28 mAb stimulated AD
skin T cell supernatant). IFN-,
TNF-, and sFas ligand (sFasL) were
used at 10 ng/ml. The target PCR
products are quantified relative to the
PCR products for the internal calibra-
tion (GAPDH) and unstimulated con-
trol keratinocytes. One representative
is shown. Same results were obtained
in two experiments from two differ-
ent donors. MIP, macrophage-inhibi-
tory protein; Ltn., lymphotactin; L32,
housekeeping gene that encodes L32
ribosomal protein.
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RNase protection assays analyzing several chemokines, IL-8 mRNA
was constitutively expressed, whereas IP-10 mRNA was up-regulated
by IFN- in human primary keratinocytes (Fig. 2A).
Increased mRNA expression of IP-10, Mig, and iTac was ob-
served by IFN- stimulation of primary human keratinocytes.
TNF- had a synergistic effect on the up-regulation of all three
chemokines by IFN-, without showing any effect alone. Anti-
CD2/CD3/CD28 mAb-stimulated AD skin T cell supernatants also
up-regulated these three chemokines. Triggering of the Fas by
sFasL did not stimulate chemokine expression alone or in addition
to IFN- and TNF- (Fig. 2B).
To confirm the mRNA expression profiles, we investigated the
IP-10, Mig, and iTac protein expression on primary human kera-
tinocytes by immunohistology. An up-regulation of IP-10, Mig,
and iTac was observed after stimulation of keratinocytes with su-
pernatant of T cells isolated from AD skin and IFN-. TNF-
alone or together with Fas-ligand did not show any effect (Fig. 3).
CXCR3 is expressed on T cells
IP-10, Mig, and iTac share the same receptor, CXCR3. We inves-
tigated the expression of CXCR3 on T cells isolated from lesional
skin of AD patients, peripheral blood T cells of healthy individu-
als, and AD patients as well as in vitro differentiated Th1 and Th2
cells. Freshly purified CD45RO cells and in vitro differentiated
cord blood CD4 Th1 and Th2 cells expressed CXCR3. Higher
expression of CXCR3 was observed on Th1 than on Th2 cells (Fig.
4A). We determined CXCR3 expression on peripheral blood T
cells of healthy individuals and atopic dermatitis patients by dou-
ble staining together with an anti-CD3 mAb. CXCR3 was ex-
pressed on 63.0  9.3% of T cells from healthy individuals and
70.2  7.2% on T cells of AD patients. There was no significant
difference (Fig. 4B). Within several chemokine receptors, CXCR3
mRNA was expressed in addition to CXCR4, CXCR5, and CCR7
mRNA on T cells, which were isolated and cultured from skin
biopsy samples of AD patients (Fig. 4C).
Enhanced T cell chemotaxis toward IFN--treated keratinocytes
The histological hallmark of eczematous lesions in the AD skin is
dermal mononuclear cell infiltration and spongioform morphology
in the epidermis. As shown in CD4 T cell staining in Fig. 5A,
some of the CD4 T cells have migrated inside the epidermis.
Several CD4 T cells have mainly concentrated in the epidermal
area, which shows substantial spongiosis. Because differential che-
motactic features of Th1 and Th2 cells have been demonstrated,
we analyzed the cytokine profile of T cells, which infiltrate the
epidermis of AD lesions. Epidermal T cells were cultured from
different AD patients, and their cytokine profile was characterized.
Epidermal T cells showed a Th0 cytokine profile with high quan-
tities of IFN-, IL-5, and IL-13 and relatively lower amounts of
IL-4 (Fig. 5B).
To analyze the role of IFN- on T cell chemotaxis, we used a
Transwell system, in which fluorescence-labeled T cells migrated
toward primary human keratinocytes separated with a 3-m pore
size filter. Enhanced migration of T cells toward IFN--treated
keratinocytes in comparison with unstimulated or TNF- treated
keratinocytes was observed. There was no difference between
CD4 Th1 and CD4 Th2 cells. TNF--pretreated keratinocytes
did not induce either CD4 Th1 or CD4 Th2 cell chemotaxis
(Fig. 5C).
Increased IP-10, Mig, and iTac expression in AD skin
The in vivo relevance of the studied hypothesis was investigated
by demonstration of the IFN--induced chemokines in AD skin
(Fig. 6). IP-10, Mig, and iTac were stained in lesional AD and
normal skin of healthy individuals by immunohistochemistry. En-
hanced IP-10 distribution was detected in the suprabasal layer of
the epidermis in lesional acute AD skin biopsies. In healthy skin,
IP-10 expression was restricted to basal keratinocytes, whereas
suprabasal epidermis did not show any expression. In AD skin,
Mig and iTac expression was more distributed within the whole
epidermis. Similar to IP-10, Mig expression was restricted to basal
keratinocytes in healthy skin, whereas stronger expression was ob-
served in suprabasal layers of lesional AD skin. In contrast, iTac
FIGURE 3. IP-10, Mig, and iTac are expressed by IFN- stimulation in
keratinocytes. Immunohistochemical staining of cultured keratinocytes
show up-regulation of IP-10, Mig, and iTac after incubation with T cell
supernatant and IFN-. Primary human keratinocytes were treated with
50% (v/v) T cell supernatant (sup.; 48 h anti-CD2/CD3/CD28 mAb-stim-
ulated AD skin T cell supernatant), IFN-, TNF-, and sFas ligand
(sFasL); u.s., unstimulated keratinocytes. IFN-, TNF-, and sFas ligand
were all used at 10 ng/ml. All original magnifications are 200. Same
results were obtained in four independent experiments.
FIGURE 4. CXCR3 is expressed on T cells. A, FACS analysis showing
that CXCR3 was expressed on CD4 Th1 cells and CD45RO cells. CD4
Th2 cells showed a lower expression of CXCR3. One of two experiments
with similar results is shown. The percent of CXCR3 T cells is shown on
the right side of each histogram. B, FACS analysis of CXCR3 and CD3 on
PBMC of seven AD patients and six healthy individuals. One demonstra-
tive FACS datum shown with mean  SD of all individuals on the upper
right quadrant. IC, isotype control Ab. C, RNase protection assay showed
expression of CXCR3, CXCR4, CXCR5, and CCR7 mRNA in anti-CD2/
CD3/CD28 mAb-stimulated skin T cells isolated from lesional epidermis
of two different AD patients. L32, housekeeping gene that encodes L32
ribosomal protein.
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was expressed both in basal keratinocytes and in suprabasal ker-
atinocytes in normal and AD skin. The expression of IP-10, Mig,
and iTac was mainly focused to epidermis. All three chemokines
were not expressed in dermis, demonstrating a chemotaxis gradient
from dermis to epidermis.
Discussion
Multiple molecules, including families of adhesion molecules and
chemokines, provide signals for the dynamic trafficking of T cells
into inflammatory tissues. Transendothelial migration and influx
into skin represent the first phase leading to dermal perivascular
infiltration by T cells in AD. Interestingly, a second step of che-
motaxis, as demonstrated in this study, takes place in the migration
of T cells closer to and into the epidermis where they augment T
cell-mediated effector functions.
Eczematous skin lesions with distinct etiology are associated
with T cell infiltration in the dermis leading to an interaction be-
tween T cells and keratinocytes and a marked keratinocyte pathol-
ogy (31). Several studies have demonstrated that IFN- is one of
the most active cytokines during T cell-keratinocyte interaction
(32, 33). IFN--producing T-cells are present in chronic AD le-
sions (21). Keratinocyte activation-induced cell death by IFN- in
the activation phase of keratinocytes might strongly contribute to
inflammation in AD. Relatively low concentrations of IFN- can
induce keratinocyte apoptosis and spongioform morphology as an
essential mechanism in the pathogenesis of eczematous dermatitis
(25, 30). ICAM-1, which is crucial for T cell retention in the epi-
dermis, is expressed on keratinocytes after exposure to IFN- (34,
35). IFN- up-regulates MHC class I molecules and Fas and in-
duces de novo synthesis of MHC class II molecules on keratino-
cytes (36, 37). IFN- also induces the expression of several cyto-
kines such as IL-1, IL-1 receptor agonist, TNF- and GM-CSF
(37, 38). TNF- and IL-17 are able to enhance the efficiency of
IFN- in activating keratinocytes (35, 39). In addition, IFN- was
demonstrated to induce squamous differentiation in epidermal ker-
atinocytes. Apoptosis induced by IFN- in the present study might
be the consequence of terminal differentiation and growth arrest
(40). Moreover, whether suppressive cytokines such as IL-10 may
inhibit IFN- secretion inside the skin during the development of
eczema lesions and during the healing process remains to be elu-
cidated (28).
The present study demonstrates that Mig, iTac, and IP-10
mRNAs are expressed in higher amounts after exposure of kera-
tinocytes to IFN-. This leads to the migration of T cells from the
dermis to the epidermis and represents a second step of chemotaxis
after the recruitment of T cells from blood. Arrest and activation of
leukocyte integrins via locally expressed chemokines are impor-
tant steps for the transmigration of T cells through the vascular
barrier. Cutaneous lymphocyte-associated Ag, CD45RO, LFA-1
and different chemokine receptors are expressed on the surface of
T cells. Beside ICAM-1, surface molecules like CD34, VCAM-1,
and E-selectin are expressed on endothelial cells and play an im-
portant role in diapedesis together with the receptors on T cells
(10). In allergic contact dermatitis, T lymphocytes transmigrate
into the dermis driven by an early chemokine gradient. Chemo-
kines, such as RANTES, MCP-1, thymus, and activation-regulated
chemokine (CCL17), pulmonary and activation-regulated chemo-
kine (CCL18), and macrophage-derived chemokine (CCL22) are
reported to be involved in this process (41). In contrast to chemo-
kines and adhesion molecules in T cell transendothelial migration,
the chemokines IP-10, Mig, and iTac are expressed on late stages
of contact dermatitis (41). In addition, IP-10 is up-regulated in the
epidermis in inflammatory skin diseases like psoriasis or allergic
contact dermatitis (42, 43).
CXCR3, the specific receptor for these chemokines, is expressed
on T cells, preferentially on Th1 cells (44–46). We detected the
FIGURE 5. Enhanced chemotaxis of CD4 T cells toward IFN--stim-
ulated keratinocytes. A, CD4 T cells infiltrating the spongiotic epidermis.
200. Magnification of the boxed area is 400. B, Epidermal T cells
showed a Th0 cytokine profile with high quantities of IFN-, IL-5, and
IL-13 and relatively lower amounts of IL-4. E, , and , unstimulated
(u.s.); F, , and f, anti-CD2/CD3/CD28 mAb stimulated. C, In vitro
differentiated CD4 Th1 and Th2 cells both showed high migration toward
IFN-- but not TNF--stimulated keratinocytes. IFN--stimulated human
keratinocytes induced T cell chemotaxis in three experiments with three
different T cell sources. SD of duplicate cultures is shown.
FIGURE 6. Increased IP-10, Mig, and iTac expression in AD skin. Rep-
resentative images from two healthy donors and eight different AD patients
are shown.200. Arrows indicate IP-10 and Mig expression on basal layer
keratinocytes in healthy epidermis and enhanced Mig, IP-10, and iTac
expression on suprabasal keratinocytes in AD.
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expression of CXCR3 on in vitro differentiated CD4 Th1 and
Th2 cells with Th1 predominance as well as on T cells isolated
from epidermis. In addition, epidermal T cells rather showed a Th0
cytokine profile with increased IFN-, IL-5, and IL-13 production.
After migration from dermis to epidermis, IFN- released from
epidermal T cells may further induce the expression of more IP-10,
Mig, and iTac on keratinocytes and further induce keratinocyte
apoptosis. Epidermal T cells also expressed CXCR4, CXCR5, and
CCR7, which bind to homeostatic chemokines (4). Interestingly,
CCR7 as a central memory T cell chemokine receptor was ex-
pressed on epidermal effector T cells (47). The reasons for the
expression of these chemokine receptors in epidermal T cells re-
main to be elucidated. Beside the function of lymphocytes as im-
munological effector cells, they also produce growth factors such
as basic fibroblast growth factor and leukocyte-derived growth fac-
tor (48–50). Their later appearance in the eczematous lesions may
additionally favor tissue formation and remodeling of the tissue
components. Accordingly, Mig and IP-10 are expressed in a later
stage of wound healing and are essential for the persistence of
lymphocyte recruitment (50). These studies on chemokines and
their receptors demonstrate a complex system of different chemo-
kines and chemokine receptors inside the skin during different mi-
gration stages of T cells.
The present study demonstrates an active interaction between
effector T cells and target keratinocytes in the AD skin. Appar-
ently, during the activation phase of T cell- and IFN--mediated
activation-induced keratinocyte death, epidermal keratinocytes re-
lease chemokines that attract T cells from dermis to closer to and
into the epidermis. The second step of chemotaxis of T cells from
the dermis to the epidermis may play an essential role in the aug-
mentation of keratinocyte apoptosis, enhanced infiltration of T
cells into the dermis, remodeling of the skin, and chronicity of AD
lesions and disease.
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6.4 Statement of contribution to publications 
 
For the publication titled “Immune responses in healthy and allergic individuals 
are characterized by a fine balance between allergen-specific T regulatory 1 and 
T helper 2 cells” (J Exp Med., 2004. 199: 1567-1575), I have performed all of the 
immunocytochemistry, as depicted in figure 5 B. Furthermore, Mübeccel Akdis 
and I cooperated in the isolation, culture and characterisation of the IL-4-, IL-10- 
and IFN-!-secreting cells used for figures 1, 2, 4 and 6, as these were also used 
for parts of the publication “Absence of T regulatory cell expression and function 
in atopic dermatitis skin”. 
 For the publication “A second step of chemotaxis after transendothelial 
migration: keratinocytes undergoing apoptosis release IFN-!-inducible protein 10, 
monokine induced by IFN-!, and IFN-!-inducible "-chemoattractant for T cell 
chemotaxis toward epidermis in atopic dermatitis” (J Immunol., 2003. 171: 1078-
1084), I performed several of the experiments with HaCaT keratinocytes that 
confirmed the results with primary keratinocytes depicted in figure 1. Sven 
Klunker and I further cooperated in the immunocytochemistry and 
immunohistochemistry used for figures 3 and 6, respectively. 
 For the first author publication “Absence of T regulatory cell expression 
and function in atopic dermatitis skin” (J allergy Clin Immunol., 2006. 117: 176-
183), I have performed the experiments used for all figures, apart from those 
depicted in figure 3A and figure 4.  
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7. Discussion 
 
Allergic diseases are controlled, mediated and in some cases executed by T 
cells. The activation, differentiation and interaction of T cells therefore form 
pivotal points in the understanding of the immunological mechanisms of allergy. 
This understanding can form the basis for a rational approach to the prevention 
and treatment of allergic disease.  
 
Traditionally, allergen-SIT was aimed at suppressing the allergen-specific 
activation of Th2 cells by inducing a shift towards a Th1 response. This idea was 
based on the hygiene hypothesis, which suggests that allergic disease results 
from a failure of the immune response to make the normal shift from a Th2-
dominated to a predominantly Th1 response within the first 40 days of life, due to 
a lower exposure to microbial antigens. However, the simultaneous rise of Th1-
related disease challenges this theory. We showed that allergy indeed does not 
result from an aberrant Th2/Th1 balance, but that it is rather the Th2 to Tr1 ratio 
that decides the outcome of an immune response to allergen (see figure 3). This 
implicates that active suppression forms an essential mechanism in inducing 
specific immunological unresponsiveness. The immunological mechanisms that 
control the shift in dominating allergen-specific subset in vivo remain unclear. In 
contrast to what was previously thought, the cytokine profile of memory T helper 
cells, and therefore the distinction between a Th1 or Th2 phenotype, may not be 
consitent, but could very well be dependent on external factors and thus show 
flexibility 143, 144. In addition, the Tr1 cells in our study did not appear to be 
anergic and could expand in vivo, as they proliferated under the influence of IL-2, 
IL-4, IL-7 and IL-15.  
We showed, by specifically blocking receptors with mAb or decoy 
receptor, that the suppressive activity of Tr1 cells depends highly on the 
suppressive cytokines IL-10 and, to a slightly lower extend, TGF-#.  These 
cytokines have been demonstrated to exert their suppressive effect on the 
induction of an immune response in several ways. First, both cytokines have           
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Figure 3. Differences between the healthy and allergic T cell response. A healthy 
immune response to allergens may not rely on the balance between Th2 and Th1 cells, 
but rather on the balance between Th2 and Treg cells. The major immunological change 
after successful allergen-SIT is characterised by a reduced Th2 response and increased 
numbers of Treg cells. Also, in healthy individuals the majority of allergen-specific T cells 
is of the Tr1 phenotype, while allergic individuals show a predominantly Th2 response. 
Adapted from Verhagen J et al., Expert Opin. Biol. Ther. 2005; 5:537-44.    
 
 
been shown to inhibit the full maturation of DC 145, 146. Immature DC do not 
express the co-stimulatory ligands and cytokines needed to successfully initiate a 
T cell response. Second, IL-10, as previously shown by our group, can inhibit T 
cell activation by intervening in the interaction of PI3K with the intracellular 
domain of the co-stimulatory receptor CD28 147. This inhibition of the CD28 
signalling pathway by IL-10 was recently shown by our group to be mediated by 
the tyrosine phosphatase SHP-1 (Taylor A et al., manuscript submitted). 
Furthermore, other co-stimulatory receptors, such as inducible costimulator 
(ICOS) and CD2, were shown to be subject to IL-10-induced inhibition in a similar 
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fashion. Interestingly, TGF-# has comparable inhibitory effects on T cell co-
stimulation, although a different phosphatase than SHP-1 might be involved 
(Verhagen J et al., unpublished observation).  
Apart from the important role of cytokines in the regulation of the allergen-
specific immune response by Tr1 cells, there is also a cell contact-dependent 
mechanism that plays a role. We demonstrated that blocking CTLA-4 or PD-1 on 
IL-10-secreting Tr1 cells reduced the suppressive capacity of these cells. The 
previous observation that the blockade of CTLA-4 is associated with decreased 
levels of TGF-# 142 could help to explain these results.    
 
A failure in the suppression of T cell activation by innocuous antigen can initiate 
allergic disease. The pathology of atopic dermatitis results from the migration and 
differentiation of activated T cells in the dermis of the skin. Once inside the 
dermis, these T cells differentiate and show a Th1/Th0 cytokine profile with high 
IFN-!, IL-5 and IL-13 production. It should be noted here that the receptor affinity 
and activation thresholds for the Th1 cytokine IFN-! and the Th2 cytokines IL-4, 
IL-5 and IL-13 differ significantly. While as little as 1 ng/ml of IFN-! suffices to 
induce keratinocyte apoptosis, 50 ng/ml of IL-4 or IL-13 are required to induce 
IgE production by B cells and the same amount of IL-5 is needed to prolong 
eosinophil lifespan in vitro 9, 148. The IFN-!-induced apoptosis of keratinocytes, 
which might be the result of terminal differentiation and growth arrest, and the 
subsequent spongiosis formation in the epidermis, are characteristic for atopic 
dermatitis.  
As we demonstrated, a second step of chemotaxis takes place during the 
migration of T cells closer to and into the epidermis, where they exert their 
effector functions. We showed that activated keratinocytes actively aggravate 
their own situation by secreting chemokines that enhance this further migration of 
T cells. IFN-! induces the upregulation of the expression of mRNA for the 
chemokines Mig (CXCL9), iTac (CXCL10) and IP-10 (CXCL11). All three 
chemokines bind to the receptor CXCR3, which is mostly expressed on Th1 cells 
and CD45RO+ cells, but also on some Th2 cells. The second step of chemotaxis 
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may thus play an essential role in the remodelling of the skin and the chronicity of 
inflammation. 
 
Our group and others, have shown the importance of the interaction between 
Treg cells and effector T cells in the control of inflammation. The central role of 
various subsets of Treg cells in the inhibition of antigen-specific T cell activation 
has been shown in models of allergy, autoimmunity, transplantation, parasitic 
infection and cancer. Also, several studies have shown a higher number of Treg 
cells in the blood of healthy individuals compared to those with hyper-immune 
disease. However, not much is known about the presence and possible role of 
Treg cells in peripheral tissues, such as the skin, gut or lungs. As already 
mentioned, IFN-! induces keratinocytes to secrete the chemokines Mig, IP-10, 
and iTac, which all share the predominantly Th1-associated chemokine receptor 
CXCR3 149, as well as TARC (CCL17) and MDC (CCL22), which bind the Th2-
associated receptor CCR4 150. Both Tr1 cells and CD4+CD25+ Treg cells express 
a vast repertoire of chemokine receptors, including CXCR3 and CCR4, thereby 
theoretically facilitating their migration into the inflamed skin 151, 152. Furthermore, 
the numbers of CD4+CD25+ T cells and CLA+CD4+CD25+ T cells have been 
demonstrated to be elevated in peripheral blood of AD patients compared to 
healthy controls or asthma patients 153, 154. We therefore investigated the 
presence of CD4+CD25+ cells in situ in the dermis and epidermis of AD and 
various other skin conditions and found that these cells did not express the 
transcription factor FoxP3, indicating that they were activated T cells and not 
Treg cells. Of notice here is that functional mutations in FoxP3 have previously 
been shown to lead to the rare IPEX syndrome in humans. This disease, also 
known as X-linked autoimmunity–allergic dysregulation (XLAAD) syndrome, is 
commonly associated with atopic dermatitis and hyper IgE responses 30. This 
suggests that the absence of FoxP3 expression in AD skin could possibly provide 
a link with the pathogenesis of this disease. In contrast to CD4+CD25+FoxP3+ 
Treg cells, we found large numbers of IL-10- and TGF-#-secreting Tr1 cells in AD 
skin.  
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The analysis of T cells isolated from the skin of AD patients showed that 
these cells highly effectively induce keratinocyte apoptosis, despite the presence 
of a substantial percentage of IL-10-secreting Tr1 cells. A defect in the sensitivity 
to regulation has previously been suggested as a determinant in the ongoing 
effector functions of AD skin T cells. Superantigens, present in the skin of more 
than 90% of AD patients, can induce strong proliferation of CD4+ and CD8+ T 
cells in the skin by non-specific crosslinking of MHC-II on antigen-presenting 
cells or activated KC and the V# region of the TCR 
155. Strong binding of 
superantigens to the TCR in conjunction with CD28 co-stimulation 156 was shown 
to render T cells insensitive to suppression by CD4+CD25+ Treg cells 157, 158 and 
IL-10 159. Superantigens also abrogate immune suppression by corticosteroids 
160, which, recent evidence suggests, operate via the induction of Treg cells 161. 
Subsequent in vitro experiments with cells that were isolated from 
peripheral blood and had not been exposed to superantigens, confirmed that Tr1 
and CD4+CD25+ Treg cells are able to suppress allergen-specific activation of 
effector T cells. However, neither of these Treg cell subsets was able to suppress 
keratinocyte apoptosis induced by pre-activated Th1 cells. Further assays based 
solely on cytokines and keratinocytes, as well as culture experiments with 
artificially generated, fully differentiated skin segments confirmed that Treg cells 
are not able to suppress the effector function of pre-activated T cells.  
 
In perspective, four distinct stages play an important role in allergic inflammation 
of the skin (figure 4). 1, the activation of T cells by APC through the presentation 
of a wide range of antigens (e.g. aeroantigens, food antigens or autoantigens) on 
their surface or by the encounter of superantigen. 2, organ-selective homing, 
whereby cells are influenced by a network of chemokines and are drawn towards 
and into the skin.  3, the prolonged survival of T cells within the inflamed skin, 
due to contact with the ECM and the encounter of survival cytokines, coinciding 
with a second step of reactivation, mainly by superantigens. 4, the effector roles 
of T cells, which result in the induction of hyper IgE production, the activation of 
 73 
eosinophils, the induction of keratinocyte apoptosis and the development of 
spongiosis, all of which are important factors in the pathogenesis of AD.  
The studies in this thesis demonstrate that Treg cells of either Tr1 or 
CD4+CD25+ phenotype can suppress allergen-specific activation of effector T 
cells (stage 1 and, if not stimulated by superantigen, stage 3) and therefore play 
an important protective role in the development of allergic disease. Furthermore, 
the upregulation of the number of Treg cells by allergen-SIT can lead to the 
induction of an immunological state whereby a response to allergen exposure is 
no longer initiated. However, in established disease such as AD, where T cells 
have been pre-activated, and have migrated to the tissues under the influence of 
a specific homing receptor or a chemokine network, neither Treg cells, nor their 
suppressive cytokines IL-10 and TGF-#, are able to directly suppress the 
destructive effector functions of activated T cells (stage 4). 
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Figure 4. The four sequential processes characterising allergic inflammation.   
(1) A wide range of known antigens and yet unidentified factors can activate T cells. (2) 
Subsequently, these T cells undergo organ-selective homing under the influence of 
organ-related chemokine networks. (3) T cells within subepithelial tissues show 
increased survival due to contact with the extracellular matrix and locally produced 
cytokines, while repeatedly being stimulated. (4) These activated T cells meanwhile 
secrete their specific cytokines, leading to apoptosis, hyper IgE and eosinophilia. 
Adapted from Taylor A et al., Int. Arch. Allergy Imunol. 2004; 135:73-82 
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